Final Pharmaceutical Jurisprudance (1)

View Final Pharmaceutical Jurisprudance (1) flipbook.

Pharmaceutical Jurisprudence in Homeopathy An Approach to Law & Ethics in Homoeopathy Dr. HIMANI SHARMA

© SIMPATHY 2026 Pharmaceutical Jurisprudence in HomoeopathyAll rights reserved All rights reserved by Publisher. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the author. Although every precaution has been taken to verify the accuracy of the information contained herein, the author and publisher assume no responsibility for any errors or omissions. No liability is assumed for damages that may result from the use of information contained within Written by ©Dr Himani Sharma, 2026 First Published in September 2026. ISBN: 978-81-687510-8-8 Price: 300/- Typographic Design: Ratna Bhaduri Distributed by: Simpathy, Amazon, Flipkart Design & composed by: Aman, Laxmi Nagar, Delhi Enquiry on: sihppsdelhi@gmail.com, editor@simpathy.org,+919968009198 Published by: SIMPATHY INSTITUTE OF HOMOEOPATHIC PHARMACY AND HOSPITAL C-79/6, Om Nagar, Badarpur, New Delhi-110044

Pharmaceutical Jurisprudence in Homeopathy An Approach to Law& Ethics in Homoeopathic Pharmacy Dr. Himani Sharma Physician & Researcher B.H.M.S (Jiwaji University, India) PBDHM (Cape Breton University, Canada) Ex-Health Coordinator (Population Research Centre, India) Clinical Informatics Intern Analyst (Nova Scotia Health, Canada) Life Member of the Indian Association for Study of Population (India) Certified in Psychologically Safe Leadership (Uni. of New Brunswick Canada)

Dedicated to my loving Parents For their love, Boundless encouragement, and sacrifice, & To all the aspiring students Whose inspiration led to this extraordinary work.

“The most important human endeavor is the striving for morality in our actions. Our inner balance and even our very existence depend on it. Only morality in our actions can give beauty and dignity to life”. - ALBERT EINSTEIN

CONTENTS Foreword .......................................................................................... 08 Preface .............................................................................................. 10 About the Author ............................................................................. 12 Syllabus ............................................................................................ 14 Introduction ...................................................................................... 15 CHAPTER-I Pharmaceutical legislation in India .............................................. 18 1.1 History of Pharmaceutical Legislation ....................................... 18 1.2 Origin & Nature ......................................................................... 21 1.3 The Drug Enquiry Committee.................................................... 24 1.4 Scope & Objectives .................................................................... 26 1.5 Evolution of the “Concept of Pharmacy” as an integral part of Health Care Systems....................................................... 29 CHAPTER-II Principle and Significance of Professional Ethics ....................... 36 2.1 Pharmaceutical code of Ethics ................................................... 36 2.2 Pharmacists in relation to the job ............................................... 39 2.3 Pharmacists in relation to the Trade ............................................... 2.4 Pharmacists in relation to the Profession ....................................... 2.5 Significance of professional ethics ............................................ 41

CHAPTER-III The Drug and Cosmetic Act, 1940 ............................................... 64 3.1 Drug and Cosmetic Act Overview ............................................. 64 3.2 The Retail and Wholesale Distribution of Drugs ....................... 66 3.3 The Power of Inspectors ............................................................ 69 3.4 The Facilities of a Pharmacy .......................................................... 3.5 The Schedules and their Special References.............................. 73 3.6 The Salient Features of the Labeling and Storage ..................... 75 CHAPTER-IV Drugs and Cosmetics Rules, 1945……………………………. 4.1 Introduction and Definitions 4.2 Rules applicable to homoeopathic medicines 4.3 Licensing requirements in Homoeopathy 4.4 Labeling and Packaging 4.5 Sales Records and registers 4.6 Inspection, Sampling and Testing of Homoeopathic Drugs 4.7 Offences and penalties CHAPTER-V Pharmacy Act, 1948 in India......................................................... 48 5.1 Introduction of Pharmacy Act 1948 ........................................... 48 5.2 General Study of the Pharmacy Act, 1948 ................................ 52 5.3 The working of State and Central councils ................................ 54

5.4 Registration Procedure ............................................................... 57 CHAPTER-VI The Drugs and Magic Remedies Act ............................................ 82 6.1 Introduction of Drug and Magic Act.......................................... 82 6.2 Objectionable and Permitted Advertisements ............................ 85 CHAPTER-VII Narcotic Drug and Psychotropic Substances Act, 1985.............. 92 7.1 Introduction of NDPS Act.......................................................... 92 7.2 Objectives of the NDPS Act, 1985 ............................................ 93 7.3 Offenses under the NDPS Act, 1985 ......................................... 95 7.4 Punishments under the NDPS Act, 1985 ................................... 97 7.5 Enforcement and Regulatory Bodies ......................................... 98 7.6 Challenges and Criticisms.......................................................... 98 CHAPTER-VIII Acts in Pharmaceutical Jurisprudence ...................................... 104 8.1 Drug Price Control order (DPCO) .......................................... .104 8.2 The Poisons Act, 1919 ............................................................ 106 8.3 Medicinal and Toilet Preparations .......................................... 109 8.4 Medical Termination of Pregnancy Act, 1971 ......................... 112 8.5 New Drug Policy, 1994………………………………

CHAPTER- IX Environmental and Biomedical Waste Regulations 9.1 Environmental Pollution and Bio medical waste 9.2 Pharmaceutical waste and Expired medicines disposal 9.3 Chemical and Biomedical waste disposal 9.4 Responsibilities of healthcare institutions CHAPTER-X Emerging Regulatory Issues in Homoeopathic Pharmacy 10.1 Concept of E-pharmacy and Online sale of medicines 10.2 Digital prescriptions and Teleconsultation 10.3 Online advertising 10.4 E-commerce 10.5 Artificial intelligence and regulatory compliance Appendix-I - Legal Terminology and Basic Concepts Appendix-II - Bibliography -

Foreword It is with immense pleasure and enthusiasm that I pen this foreword for the remarkable book on Pharmaceutical Jurisprudence that lies before you. In an era of rapidly advancing medical science and an ever-evolving healthcare landscape, understanding the legal and regulatory aspects of pharmacy is crucial for the safe and effective delivery of healthcare services. Pharmaceutical Jurisprudence serves as the foundation upon which pharmacists navigate the intricate web of laws, regulations, and ethical principles that govern their practice. It is a discipline that combines the principles of pharmacy with the knowledge of legal frameworks, aiming to ensure the highest standards of patient safety, professional accountability, and ethical conduct. This comprehensive book provides a deep exploration of the legal and regulatory dimensions that shape the field of pharmacy. It covers a broad spectrum of topics, ranging from the history and development of pharmaceutical laws to the ethical considerations and professional responsibilities of pharmacists. The author has meticulously compiled a wealth of information, examining the intricate relationship between pharmacy, law, and ethics with a keen eye for detail and a commitment to accuracy.

Through the pages of this book, readers will gain invaluable insights into the legal framework that governs the manufacturing, distribution, and dispensing of medications. It explores the complexities of pharmacy practice in various healthcare settings, including community pharmacies, hospitals, and clinical research environments. Furthermore, it delves into the ethical dilemmas that pharmacists may encounter and offers guidance on navigating these challenges while upholding the highest standards of patient care. The author has thoughtfully incorporated examples, and practical scenarios to illustrate the application of pharmaceutical jurisprudence in real-world situations. This approach not only enhances the readers' understanding of the subject matter but also equips them with the tools to apply legal principles to their daily practice, ensuring the provision of safe and ethical pharmaceutical care. I commend the author for her dedication to producing a comprehensive resource that meets the needs of pharmacy students, practicing pharmacists, and legal professionals. Her expertise and commitment to excellence shine through in the depth of research, clarity of explanation, and relevance of the content presented within these pages. I fervently believe this book will serve as an indispensable guide for all those seeking a comprehensive understanding of Pharmaceutical Jurisprudence. Students will find it to be an invaluable resource for their studies, while practitioners will benefit from its practical insights and up-to-date legal information.

I extend my deepest appreciation to the author for her significant contribution to the field of pharmaceutical jurisprudence through the creation of this exceptional book. I hope that readers will find within these pages the knowledge and inspiration to navigate the complex intersection of pharmacy and law, promoting patient safety, upholding professional integrity, and advancing the field of pharmacy. Dr. R Kant Director SIMPATHY Institute of Homeopathic Pharmacy and Hospital

Preface Welcome to the intriguing realm of Pharmaceutical Jurisprudence, where the worlds of pharmacy and law intersect to ensure the safe and responsible practice of pharmacy. In this book, we embark on a journey through the legal and regulatory landscape that governs the pharmaceutical industry and pharmacy profession. Pharmaceutical Jurisprudence plays a vital role in safeguarding public health and ensuring the ethical conduct of pharmacists. It encompasses a diverse range of topics, including drug regulation, intellectual property rights, professional ethics, and the legal framework surrounding pharmaceutical research and development. This book serves as a comprehensive guide, shedding light on these complex subjects and their implications for the pharmacy profession. Pharmacists are entrusted with the critical task of handling medications, counseling patients, and making informed decisions that impact the well-being of individuals and communities. Understanding the legal and ethical boundaries within which pharmacists operate is essential for maintaining the highest standards of patient care and professional integrity. This book aims to provide aspiring pharmacists, practicing professionals, and legal scholars with the knowledge and insights necessary to navigate this dynamic landscape. Within these pages, you will find a wealth of information and analysis, carefully compiled in this field. I have drawn upon a deep understanding of pharmaceutical sciences, legal frameworks, and ethical considerations to present a

comprehensive exploration of Pharmaceutical Jurisprudence. I have incorporated this book to illustrate the application of legal principles to pharmacy practice, making the content accessible and relevant. As you journey through this book, you will discover the intricate interplay between pharmaceutical laws, regulations, and professional ethics. You will gain a nuanced understanding of the responsibilities and obligations of pharmacists, from drug procurement and storage to dispensing practices and patient counseling. Pharmaceutical Jurisprudence is a rapidly evolving field, shaped by scientific advancements, societal needs, and the ever-changing legal landscape. This book strives to reflect the latest developments, incorporating up-to-date information and addressing contemporary issues facing pharmacists today. It serves as a reference point for understanding the complexities of pharmaceutical regulation and enables readers to stay abreast of new laws, guidelines, and ethical standards that shape the pharmacy profession. I express my heartfelt appreciation to Dr. R Kant for motivating me to write this book. His passion for both pharmacy and law shines through in the comprehensive coverage, meticulous research, and clarity of exposition. Writing this book has been a journey enriched by the unwavering support and love of my family. I am deeply grateful to my parents, whose unwavering support and encouragement have been the bedrock of my journey. Their

belief in my aspirations and their sacrifices have shaped me into the person I am today. To my siblings and grandmother, whose love and understanding have been a constant source of strength, I owe a debt of gratitude. Your unwavering support has been instrumental in every step of this endeavor. I extend heartfelt appreciation to my husband, whose steadfast love, patience, and encouragement have been my anchor. Your belief in my dreams and your unwavering support have been a source of inspiration throughout this journey. This book is a testament to the invaluable role each of you has played in my life. Your love, guidance, and encouragement have fueled my passion for knowledge and dedication to my profession. This book is as much yours as it is mine, and I am grateful beyond words for each of you. I extend my deepest gratitude to the readers who embark on this journey with us. It is my sincerest hope that this book serves as a guiding light, empowering you to embrace the legal and ethical dimensions of pharmacy practice, champion patient safety, and uphold the noble values that underpin the pharmacy profession. Dr. Himani Sharma

About the Author Dr. Himani Sharma is a distinguished professional in the fields of medicine and research. With a deep-rooted passion for improving healthcare outcomes and advancing scientific knowledge, Dr. Himani has dedicated her career to making significant contributions to both clinical practice and research. Dr. Himani Sharma brings a rich tapestry of experience and expertise to the field of healthcare and research. She holds a bachelor’s degree in Homeopathic Medicine and Surgery from Jiwaji University, India, marking the beginning of a distinguished career dedicated to advancing healthcare practices. Her extensive training and experience in the medical field have equipped her with a comprehensive understanding of the complexities of human health and the challenges faced in delivering quality patient care. In addition to her clinical work, Dr. Himani has a profound research interest. She has actively engaged in cutting-edge studies, exploring innovative approaches to disease prevention, diagnosis, and treatment. As a researcher, Dr. Himani has focused on pushing the boundaries of medical knowledge, seeking advancements that have the potential to transform patient care. Her expertise extends to various areas, where she has made notable contributions to the understanding and management of complex medical conditions. Throughout her career, Dr. Himani has served in multifaceted roles as a physician, researcher, and pivotal state lead for biomarkers, contributing significantly to the standardization of biomarkers in healthcare practices. Her tenure as a health coordinator for NCT Delhi

under the Ministry of Health and Family Welfare, Government of India, underscored her commitment to enhancing healthcare delivery through rigorous research and innovative methodologies. Dr. Himani's academic journey has been equally illustrious. She has imparted her knowledge as an assistant professor at the Simpathy Institute of Homeopathy Pharmacy and honed her skills as a clinical informatics intern analyst in the international healthcare sector. Her time with the Provincial Health Authority, Nova Scotia Health, in Canada, further enriched her understanding of healthcare dynamics on a global scale. With a profound interest in healthcare management, Dr. Himani pursued post-baccalaureate studies in Healthcare Management in Canada, delving into critical areas such as healthcare policy, analytics, project management, legal and ethical considerations, public health, and organizational behavior. Her expertise extends to health informatics and electronic health records (EHR), reflecting her proactive approach to integrating technology with healthcare delivery. She is a dedicated professional who continually seeks to broaden her knowledge and skills. She holds certifications in CPR/AED/First Aid from the National CPR Foundation, Canada, Taking Ownership in Palliative Care from Pallium Canada, and Workplace Hazardous Material Information System (WHMIS) 2015 Canada, underscoring her commitment to professional development and patient care excellence. Beyond her professional pursuits, Dr. Himani actively engages in mentor ship and education. She has supervised and mentored aspiring medical professionals, guiding her in their journey to

become competent and compassionate practitioners. Dr. Himani is committed to nurturing the next generation of healthcare leaders and fostering a culture of continuous learning and professional development. Throughout their career, Dr.Himani has remained dedicated to improving healthcare on a broader scale. She actively participates in medical organizations, committees, and conferences, where they contribute their expertise and insights to shape healthcare policies and practices. Her commitment to advocacy and patient-centered care is evident in their work and interactions with colleagues and patients. As an author, Dr. Himani seeks to share their knowledge and experiences with a wider audience. Her goal is to empower readers with the latest medical insights, research advancements, and evidence-based practices. By blending their clinical expertise and research acumen, Dr. Himani aims to bridge the gap between scientific discovery and its practical application in healthcare. Dr. Himani welcomes feedback, questions, and discussions related to the topics covered in this book. She remains committed to her ongoing quest for knowledge, collaboration, and the pursuit of excellence in medical practice and research.

Introduction The study of pharmacy rules and laws, pharmacy protocols, and drugs and medicine is known as Pharmaceutical Jurisprudence. Every country regulates pharmacists, pharmacies, medications, and pharmaceuticals. As a result, budding pharmacists in Pharmacy medical colleges must be acquainted with the legislation that governs their professional actions in their respective pharmaceutical workforce in the future. Pharmaceutical jurisprudence has historically been an element of pharmacy education. This book will assess students' knowledge and aptitude for applying laws, rules, and policies in pharmacy practice. The guidelines in Pharmaceutical Jurisprudence govern pharmacy practice as well as medication manufacture, distribution, advertising, sale, and usage. In

addition to improving health care and fostering well-being, pharmacists are experts in pharmaceuticals. In a student’s capacity as a pharmacist, they will use their expertise to write and deliver prescriptions, check on the accuracy of medications and doses, avoid dangerous drug interactions, and advise patients on the safe and proper use of their medications. Being a pharmacist will provide students with a unique and specialized understanding of how medications are made and used, as well as their chemical, biological, and physical qualities. Laws about the pharmacy are always introduced to pharmacy students. To grasp the provisions of the law in their true significance, one must first understand the context in which they were enacted. Professional students are constantly educated about the essential laws that regulate their field and its operations. In the case of pharmacy, such topics are taught as forensic pharmacy or pharmaceutical jurisprudence. Previously, the field of forensic pharmacy encompassed pharmacy-related legislation such as Acts, Rules, Orders, Regulations, and other comparable features. Professional ethics is also taught as part of the forensic pharmacy program. Forensic pharmacy is now frequently substituted by a more attractive word - Pharmaceutical Jurisprudence.

C H A P T E R - 1

C H A P T E R - 1 PHARMACEUTICAL LEGISLATION IN INDIA LEARNING OBJECTIVE ➢ To understand the origin and nature or history of pharmaceutical legislation in India ➢ To understand the Drug Enquiry committees. ➢ To understand the scope and objectives of Pharmaceutical Legislation in India. ➢ To understand the evolution of the concept of pharmacy as an integral part of healthcare systems. 1.1 HISTORY OF PHARMACEUTICAL LEGISLATION IN INDIA The origin and development of pharmaceutical legislation in India is a fascinating journey that reflects the country's evolving healthcare landscape and the need to regulate the pharmaceutical industry. Understanding the historical context and the progression of pharmaceutical legislation provides valuable insights into India's current regulatory framework governing the production, distribution, and sale of medicines. The history can be traced back to the colonial era when the British East India Company established control over various

aspects of governance, including healthcare. During this period, the focus was primarily on regulating the importation and sale of drugs, emphasizing protecting British interests rather than ensuring public health. One significant milestone in the development of pharmaceutical legislation was the enactment of the Drugs and Cosmetics Act in 1940. This legislation marked a shift towards a more comprehensive and structured approach to drug regulation. The Act aimed to safeguard public health by setting standards for drug quality, safety, and efficacy, as well as regulating the import, manufacture, and sale of drugs and cosm

1.1.1 The Emergence of Modern Medicine and Pharmacy Historically, medicines in India were created from natural resources, namely vegetables and plants, and their by-products. In certain cases, animal and mineral materials were also utilized. Ayurveda was an Indian medical practice system. Drugs were not nearly as strong in those days as they are now. Their production, storage, and usage were not organized and scientific, and very few specialized methods were applied in those areas. Medicines were produced based on empirical notions back then. For all these reasons, there was no governmental oversight of pharmaceutical manufacturing and distribution. Such measures were unnecessary. The modern medical system (also known as the allopathic medical system) was brought to India by British businessmen who subsequently became rulers in the late nineteenth century. The British ruled during their reign. Allopathic medicine was purposely favored. Initially intended for the ruling elite, the allopathic or Western system of medicine gained popularity among the people of India by the end of the nineteenth century. 1.1.2 India's pharmacy in the Nineteenth and early twentieth centuries Though the Western system of medicine grew popular in India during the nineteenth century, it had a commercial attitude and interest with very little scientific basis. Concepts of service and

professionalism. Allopathic medications were known by other titles, including Western medicine, modern medicine, and allopathic medicines. The most common appellation, however, was "English medicines," because these medications were brought from England and were used by English manufacturers and entrepreneurs. By the end of the twentieth century, service principles, in addition to financial concerns, had evolved into a vital part of modern medical practice, including sales. Consequently, mediocre, Fake, and other counterfeit drugs became highly frequent in the country, and in some instances, they were more prevalent than genuine and high-quality ones. Drugs were frequently made in foreign nations solely for the Indian market. For instance, pharmaceuticals were made in other nations just for the Indian market, and they were of inferior quality in comparison to their domestic market products. There was no system in place in India to regulate or govern the disastrous situation and seize control of the pharmaceutical company. The identification and evaluation of the legitimacy of medications accessible on the Indian market were beyond the capability of medical practitioners. Except for the Poison Act of 1919, there were no regulations in India to control and manage the import, production, and sale of therapeutic agents of any type, powerful or inert. True, there were provisions in the Indian Penal Code about toxic substances, but they were ineffective in controlling the problem. All true practitioners of medicine sought instruction and help from the rulers and the state.

1.1.3 Legislation enacted during the British Rule The following are the laws that existed in India throughout the nineteenth and the early twentieth century that had control or relation with drugs and other medicinal substances. • The Indian Penal Code (IPC) defines deliberate adulteration of any medicines reducing its efficacy, making it toxic, or changing its function. Only adulteration that rendered a medicine "noxious," "less efficacious," or "altered its operation" was made criminal under the Indian Penal Code provisions. • The Opium Act of 1978 governed poppy cultivation, as well as the manufacturing, possession, transportation, export, import, and sale of opium. • The Indian Merchandise Act of 1889 was concerned with the mis-branding of Indian goods commodities in general, as well as the penalties for such offenses. • The Indian Tariff Act of 1894 and the Sea Customs Act of 1898 impose customs duties on commodities such as medications, medicines, chemicals, and foods imported into or exported from India. • The Poisons Act of 1919 merely governed the importation, possession, and sale of poisons. • The Cantonment Act of 1924 authorized cantonment officials to enter any business and seize any 'adulterated' medication or medicine. There was, however, no exact definition of an adulteration or contaminated substance.

• The Dangerous Narcotics Act of 1930 was designed to regulate activities such as cultivation and production, possession, import, export, transit, and sale of dangerous drugs such as Coca, Hemp, and Opium. Certain parts of the Opium Act of 1878 were incorporated. • The Bengal Food Adulteration Act 1919, the Bengal Excise Act 1909, the Madras Prevention of Adulteration Act 1919, the Bombay Prevention of Adulteration Act 1925, the United Provinces (now Uttar Pradesh) Prevention of Adulteration Act 1912, and the Bihar and Orissa Prevention of Adulteration Act 1919 were all state enactments. They all, however, failed to address the many regulatory elements of medications and pharmaceuticals. DID YOU KNOW ? India's pharmaceutical regulatory system is known for its robust generic drug industry. The country is referred to as the "Pharmacy of The World" due to its large-scale production and export of affordable generic medicines. 1.2 ORIGINS AND NATURE • In ancient years, the Ayurveda system of medicines was popular in India. Indians were depending on the indigenous

source of medicines. The allopathic system of medicine was introduced to India due to the invasion of the British. • In Calcutta, the first chemist shop was introduced by Mr. Bathgate in the year 1811. It took about 100 years for this firm to develop the first tinctures and spirits. • In the year 1821, Smith Stanistreet and Co. started a new shop, and in the year 1918, the manufacturing. The process was adopted by this firm. • Acharya Prafulla Chandra Roy started a new company called Bengal Chemical and Pharmaceutical Works, in Calcutta in the year 1901. • In 1903, the initiative was taken by Prof. T. K. Gajjar, who established Alembic Chemical Works Ltd. At Baroda. All the above establishments could not satisfy the need of the population and hence, many medicines were imported to India. After the First World War, there was a drastic change in the import of medicines. Many cheap drugs were imported to India. The competition developed between foreign company drugs and indigenous drugs, as a result, many filthy practices came into the picture which resulted in the development of inferior mis-branded and spurious drugs. This led to a harmful impact on the public. Due to the ill effects of the drug, the government of India was bound to implement legislation pertaining to the import, export, manufacture, distribution, and sale of the drug. As a result, acts like the Opium Act of 1878, the Poison Act of 1919, and the Dangerous Drug of Act of 1930 came into force. These acts were insufficient for the safety of the rampant growing population and the flourishing

pharma industries. Therefore, Drug Enquiry Committee was established. The history of pharmaceutical legislation in India spans several decades and reflects the country's efforts to regulate the pharmaceutical industry and ensure the availability of safe, effective, and quality medicines to its population. The journey of pharmaceutical legislation in India can be broadly divided into four major phases: the pre-independence era, the post- independence period, the liberalization era, and the current regulatory framework. Pre-Independence Era: During the pre-independence era, the regulation of pharmaceuticals in India was limited. The British East India Company held control over drug imports and sales, primarily to protect their own interests. The introduction of the Poison Act in 1904 marked one of the earliest attempts to regulate the import and sale of poisonous substances, including drugs. Post-Independence Period: With India gaining independence in 1947, the focus shifted towards establishing a robust regulatory framework for pharmaceuticals. In 1940, the Drugs and Cosmetics Act was enacted, which laid the foundation for modern pharmaceutical legislation in India. The Act aimed to ensure the quality, safety, and efficacy of drugs and cosmetics and regulated their import, manufacture, distribution, and sale. The 1940 Act underwent several amendments to address emerging challenges and align with international standards.

Notable amendments included the introduction of provisions for clinical trials, patent protection, and drug approvals. The Drugs and Cosmetics Rules were also formulated to provide specific guidelines and procedures for implementing the Act. Liberalization Era: In the 1990s, India embarked on economic liberalization, leading to significant changes in the pharmaceutical industry and its regulatory landscape. The introduction of the Patent Act in 1970, which allowed only process patents for pharmaceuticals, played a crucial role in shaping the Indian pharmaceutical sector. This act promoted the domestic production of affordable generic medicines, making India the "pharmacy of the developing world." During this period, the Indian pharmaceutical industry witnessed substantial growth and became globally recognized. However, concerns about intellectual property rights and the need for stronger regulatory oversight prompted further amendments to the Drugs and Cosmetics Act and the introduction of new regulations. Current Regulatory Framework: In recent years, the regulatory framework for pharmaceuticals in India has undergone significant transformations to align with international practices and address emerging challenges. The establishment of the Central Drugs Standard Control Organization (CDSCO) as the primary regulatory authority has strengthened the governance and oversight of the pharmaceutical sector.

Important developments include the introduction of the Schedule M Good Manufacturing Practices (GMP) guidelines to ensure quality standards in manufacturing facilities, the establishment of the National Pharmaceutical Pricing Authority (NPPA) to regulate drug prices, and the implementation of the Clinical Trials Registry of India (CTRI) for transparent and ethical conduct of clinical trials. India has also made efforts to harmonize its pharmaceutical regulations with international guidelines. It is a signatory to the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which has influenced the protection of intellectual property rights in the pharmaceutical sector. Looking ahead, India continues to address various challenges, such as ensuring access to affordable medicines, combatting counterfeit drugs, and strengthening pharmacovigilance systems. Ongoing amendments and reforms aim to streamline regulatory processes, enhance transparency, and align with global best practices. The history of pharmaceutical legislation in India reflects the country's commitment to ensuring the availability of safe and effective medicines to its population. Through a comprehensive regulatory framework, India strives to balance public health concerns, innovation, and access to affordable medicines, contributing to the overall well-being of its citizens.

Studying the origin and nature of pharmaceutical legislation in India provides a deeper understanding of the regulatory framework that governs the pharmaceutical industry. It sheds light on the historical, social, and economic factors that have shaped the evolution of drug regulation in the country. DID YOU KNOW ? On August 11th, 1930, the Government of India established a committee, headed by Late Col. R.N. Chopra, to investigate the issues facing pharmacy in India and make recommendations for solutions. In 1931, this committee released a report. It was claimed that there was no official pharmacy specialty profession!!!! 1.3 THE DRUG ENQUIRY COMMITTEE Drug Enquiry Committees (DECs) have played a significant role in shaping pharmaceutical regulation in India. These committees have been instrumental in conducting inquiries, investigations, and evaluations related to drugs and pharmaceuticals, ensuring the safety, efficacy, and quality of medicines available in the market. Here are some notable Drug Enquiry Committees in India:

• Bhore Committee (1946): The Bhore Committee, formally known as the Health Survey and Development Committee, was established in 1943 and presented its report in 1946. Although not specifically a drug enquiry committee, it made significant recommendations for the regulation of drugs and pharmaceuticals in India. The committee emphasized the need for a comprehensive drug policy, including regulations for drug production, importation, distribution, and pricing. • Mashelkar Committee (2003): The Mashelkar Committee, officially known as the Committee on Pricing and Availability of Medicines, was formed in 2003 to examine issues related to drug pricing and availability. The committee made several recommendations, including measures to improve access to affordable medicines, encourage domestic manufacturing, and enhance transparency in the drug pricing mechanism. • Kokate Committee (2013): The Kokate Committee, also known as the Expert Committee for Review of the National List of Essential Medicines (NLEM), was constituted in 2013. The committee's primary objective was to review and update the NLEM, which serves as a reference for the essential medicines list in India. The committee assessed the therapeutic efficacy, safety, and cost-effectiveness of drugs and recommended additions and deletions to the NLEM.

• Hathi Committee (2014): The Hathi Committee, formally known as the Committee to Assess the Impact of Recent Policy Measures on the Pharmaceutical Industry, was formed in 2014. The committee examined the impact of various policy measures on the Indian pharmaceutical industry, including issues related to intellectual property rights, pricing, and regulations. The committee's recommendations aimed to promote the growth and competitiveness of the Indian pharmaceutical sector. • Verma Committee (2015): The Verma Committee, officially known as the Committee on the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002, was constituted in 2015. Although primarily focused on medical ethics, the committee also addressed issues related to the pharmaceutical industry. It recommended measures to curb unethical practices in the promotion and marketing of medicines, ensuring responsible and ethical behavior among healthcare professionals. These are just a few examples of Drug Enquiry Committees that have played significant roles in shaping pharmaceutical regulation in India. These committees have provided valuable recommendations and guidance to enhance drug safety, accessibility, affordability, and ethical practices in the pharmaceutical sector. Their efforts contribute to the overall objective of safeguarding public health and ensuring the availability of quality medicines to the Indian population.

Pharmaceutical Legislation Pharmaceutical Legislation is made to ensure that patients receive pharmaceuticals of the requisite quality, which have been examined and validated for efficacy and safety for their intended purpose. The scope and objectives of pharmaceutical legislation in India are extensive and multifaceted. They encompass a wide range of aspects related to regulation, quality assurance, safety, accessibility, pricing, and ethical practices in the pharmaceutical industry. The primary scope and objectives of pharmaceutical legislation in India include: a) Drug Safety and Efficacy: One of the foremost objectives of pharmaceutical legislation is to ensure the safety and efficacy of drugs available in the market. This involves setting standards for drug manufacturing, testing, and quality control to ensure that pharmaceutical products meet established safety and efficacy criteria. It includes regulations governing drug ingredients, dosage forms, labeling, packaging, and storage conditions.

b) Drug Quality Assurance: Pharmaceutical legislation aims to establish and enforce quality assurance measures throughout the drug supply chain. This includes regulations for Good Manufacturing Practices (GMP) to ensure that drugs are manufactured under stringent quality control standards. It also covers quality control testing of drugs, inspections of manufacturing facilities, and compliance with quality standards. c) Drug Registration and Approval: Pharmaceutical legislation provides guidelines and procedures for the registration and approval of drugs. It defines the requirements and documentation necessary for the submission of drug applications and the evaluation process conducted by regulatory authorities. The objective is to ensure that only safe, effective, and quality drugs are approved for marketing and distribution. d) Drug Pricing and Availability: Another key objective of pharmaceutical legislation is to address issues related to drug pricing and availability. This involves establishing mechanisms for pricing control and regulation to ensure affordability and accessibility of essential medicines. Pharmaceutical legislation may include provisions for price controls, ceiling prices, and guidelines for the pricing of drugs. e) Intellectual Property Rights: Pharmaceutical legislation also addresses intellectual property rights in the pharmaceutical sector. It includes provisions for

patent protection, data exclusivity, and other forms of intellectual property protection. Balancing the interests of innovator pharmaceutical companies and the availability of affordable generic medicines is a critical aspect of pharmaceutical legislation. f) Pharmacovigilance and Adverse Drug Reaction Monitoring: Pharmaceutical legislation establishes systems for pharmacovigilance and monitoring of adverse drug reactions. This involves the reporting, investigation, and assessment of adverse events associated with pharmaceutical products. It aims to ensure that timely action is taken to minimize risks and improve patient safety. g) Promotion and Marketing Practices: Pharmaceutical legislation regulates the promotion and marketing practices of pharmaceutical companies. It includes guidelines for ethical promotion, restrictions on advertising claims, and measures to prevent misleading information or unethical practices in drug promotion. The objective is to promote responsible marketing practices and protect patients' interests. h) Clinical Trials and Research: Pharmaceutical legislation governs the conduct of clinical trials and research involving human subjects. It sets out guidelines and regulations to ensure the ethical conduct of clinical trials, protection of participants' rights, and the integrity of scientific

research. It also includes provisions for the informed consent process, trial registration, and monitoring of trial conduct. i) Consumer Protection and Patient Rights: Pharmaceutical legislation seeks to protect consumer rights and ensure patient safety. It includes provisions for product liability, consumer rights, and mechanisms for addressing complaints and grievances related to pharmaceutical products. The objective is to safeguard patients' interests and ensure access to safe and effective medicines. j) Regulatory Compliance and Enforcement Pharmaceutical legislation establishes regulatory authorities and mechanisms for monitoring and enforcing compliance with regulatory requirements. It includes provisions for inspections, audits, and penalties for non-compliance. The objective is to maintain regulatory oversight, deter violations, and maintain the integrity of the pharmaceutical industry. Overall, the scope and objectives of pharmaceutical legislation in India aim to safeguard public health, ensure the availability of safe and effective medicines, promote ethical practices, protect consumer rights, and foster innovation in the pharmaceutical sector. It is a comprehensive framework designed to address the multifaceted challenges and requirements of the pharmaceutical industry in India. India has been actively engaged in international collaborations and partnerships in the field of pharmaceutical regulation. The country participates in regulatory harmonization initiatives,

shares expertise, and collaborates with international organizations such as the World Health Organization (WHO) and the World Trade Organization (WTO). DID YOU KNOW ? India has been actively engaged in international collaborations and partnerships in the field of pharmaceutical regulation. The country participates in regulatory harmonization initiatives, shares expertise, and collaborates with international organizations such as the World Health Organization (WHO) and the World Trade Organization (WTO).

1.5 THE EVOLUTION OF THE “CONCEPT OF PHARMACY” AS AN INTEGRAL PART OFHEALTHCARE SYSTEMS The concept of pharmacy as an integral part of healthcare systems has evolved significantly over time, reflecting the changing needs and advancements in medical practice. From its ancient origins to the modern era, the role of pharmacy has expanded beyond the mere dispensing of medications to encompass various aspects of patient care, drug therapy management, and public health.

Here is an overview of the evolution of the concept of pharmacy within healthcare systems: • Ancient and Traditional Practices: Pharmacy has roots in ancient civilizations, where healers, herbalists, and apothecaries played a crucial role in providing remedies and medicinal preparations. Ancient civilizations such as Mesopotamia, Egypt, Greece, and China had developed systems of plant-based medicines and compounding practices. The focus was on the preparation, preservation, and administration of herbal remedies. • Formalization of Pharmacy Education: Pharmacy began to evolve as a recognized profession during the Middle Ages and the Renaissance. The establishment of universities and medical schools led to the formalization of pharmacy education, with the introduction of dedicated courses and training programs. The emphasis was on the study of medicinal plants, compounding techniques, and pharmaceutical preparations. • Professionalization and Regulation: During the 19th and early 20th centuries, the pharmacy profession underwent significant professionalization and regulation. The establishment of professional organizations, such as pharmaceutical societies and associations, aimed to standardize pharmacy practice and ensure the competence of practitioners. Governments began to enact legislation to

regulate the practice of pharmacy, including requirements for licensure, pharmacy premises, and drug quality. • Advancements in Drug Manufacturing and Dispensing: The industrial revolution and advancements in chemistry and pharmaceutical sciences brought about significant changes in drug manufacturing and dispensing practices. The development of synthetic drugs, the standardization of drug formulations, and the introduction of dosage forms led to a shift from compounding practices to mass production. Pharmacies became important hubs for the safe and accurate dispensing of medications. • Clinical Pharmacy and Patient Care: The concept of pharmacy expanded further in the mid-20th century with the emergence of clinical pharmacy. Clinical pharmacists started playing a more active role in patient care, collaborating with physicians and healthcare teams to optimize drug therapy outcomes. Clinical pharmacy introduced the concepts of medication review, drug interactions, adverse drug reactions, and patient counseling to improve patient safety and efficacy of treatments. • Pharmaceutical Care and Pharmacotherapy: In recent decades, the concept of pharmaceutical care has gained prominence. Pharmaceutical care focuses on the direct patient care aspects of pharmacy practice, emphasizing the pharmacist's role in ensuring rational medication use, medication therapy management, and patient education.

Pharmacotherapy, the science of selecting and optimizing drug therapies, has become a critical component of pharmacy practice, with pharmacists actively involved in therapeutic decision-making. • Integration into Healthcare Systems: Today, pharmacy has evolved into an integral part of healthcare systems worldwide. Pharmacists are recognized as essential healthcare professionals, contributing to patient care, disease management, and public health initiatives. They collaborate with other healthcare providers, and participate in medication reconciliation, immunizations, chronic disease management, and public health campaigns. Pharmacists also play a vital role in pharmaceutical research, drug development, and pharmacovigilance.

Overall, the concept of pharmacy has transformed from a traditional craft to a patient-centered profession within healthcare systems. The evolving roles and responsibilities of pharmacists reflect the recognition of their expertise in drug therapy management, patient counseling, and ensuring the safe and effective use of medications. As healthcare systems continue to evolve, pharmacy will remain an indispensable component of comprehensive patient care. Let’s Revise! • The main objective of Pharmaceutical Legislation in India is to ensure that patients receive medicines of the desirable quality, which have been examined for their efficacy and safety in achieving the desired outcome. • Pharmaceutical legislation in India traces back to the colonial era, with the British implementing regulations to govern the manufacture, sale, and distribution of drugs. • Post-independence, India developed its own set of pharmaceutical laws to address public health concerns and ensure the quality, safety, and efficacy of pharmaceutical products. • Drug Enquiry Committees (DECs) were established to investigate issues related to drugs, including their safety, efficacy, and manufacturing practices. These committees

played a crucial role in shaping pharmaceutical regulations by providing recommendations and insights for policy formulation. • The primary scope of pharmaceutical legislation in India is to safeguard public health by regulating the entire drug lifecycle, from manufacturing to distribution and usage. • Objectives include ensuring the quality, safety, and efficacy of pharmaceutical products, promoting rational drug use, and preventing the entry of substandard or counterfeit drugs into the market. • Pharmacy has evolved from a mere dispensing role to a pivotal component of healthcare systems, contributing to patient care, medication management, and public health initiatives. • Regulatory frameworks have adapted to recognize the expanded role of pharmacists, emphasizing their involvement in medication counseling, adherence monitoring, and collaborative healthcare practices.

1. What is the objective of Indian pharmaceutical law? 2. Write a note on the origins and evolution of Indian pharmaceutical law. 3. What were the Drug Enquiry Committee's recommendations? 4. Briefly describe the scope and goals of pharmaceutical legislation in India.

C H A P T E R - 2

C H A P T E R - 2 PROFESSIONAL ETHICS LEARNING OBJECTIVE ➢ To understand the meaning of professional ethics ➢ To understand the principles of professional ethics ➢ To understand the significance of professional ethics INTRODUCTION Professional ethics refers to the principles, values, standards, and moral responsibilities that guide the behaviour and conduct of individuals while performing their professional duties. It helps professionals distinguish between appropriate and inappropriate conduct and encourages them to act with honesty, integrity, responsibility, fairness, and respect. In the healthcare and pharmaceutical professions, professional ethics has particular importance because the decisions and actions of professionals can directly affect the health, safety, dignity, and well-being of patients. A healthcare professional is therefore expected not only to possess adequate knowledge and technical skills but also to demonstrate ethical behaviour in every aspect of professional practice. Professional ethics establishes standards for relationships between the professional and patients, colleagues, employers,

regulatory authorities, and society. It includes principles such as confidentiality, informed consent, respect for patients, non- discrimination, professional competence, accountability, honesty, transparency, and avoidance of conflicts of interest. For pharmacy professionals, ethical practice extends from the procurement and storage of medicines to dispensing, counselling, documentation, inventory management, and patient care. A pharmacist must ensure that medicines are handled and supplied responsibly and that the patient's interests remain a primary consideration. Ethical conduct also requires compliance with applicable laws, professional standards, and institutional policies. Thus, professional ethics is not merely a collection of rules; it is a framework for developing trustworthy, responsible, and patient-centred professionals. It strengthens the reputation of the profession and contributes to safe, effective, and equitable healthcare delivery. 2.1 PHARMACEUTICAL CODE OF ETHICS The Code of Pharmaceutical Ethics provides professional and ethical principles that guide pharmacists in their conduct toward patients, the public, medical professionals, colleagues, the pharmacy profession, and society. In India, the Code of Pharmaceutical Ethics is associated with the Pharmacy Council

of India (PCI) and is included in pharmacy education as an important component of professional conduct. 2.1.1 Introduction Pharmacy is a healthcare profession in which the pharmacist has an important responsibility for the safe handling, preparation, storage, dispensing and distribution of medicines. Since medicines can significantly affect human health, pharmacists are expected to maintain high standards of professional conduct and place the welfare of patients and the public at the forefront of their professional responsibilities. The Code emphasizes that a pharmacist should: • Protect the health and safety of patients. • Maintain professional integrity and dignity. • Follow applicable laws and professional standards. • Provide pharmaceutical services responsibly. • Maintain confidentiality of patient information. • Avoid practices that may promote irrational or unsafe use of medicines. • Cooperate with other healthcare professionals. • Maintain and improve professional knowledge. • Uphold the reputation of the pharmacy profession. 2.1.2 Objectives of the Code of Pharmaceutical Ethics The major objectives are to:

1. Protect patients and the public from unsafe pharmaceutical practices. 2. Establish standards of professional conduct for pharmacists. 3. Promote honesty, integrity and responsibility in pharmacy practice. 4. Ensure the appropriate and safe supply of medicines. 5. Maintain confidentiality of patient information. 6. Promote cooperation between pharmacists and other healthcare professionals. 7. Prevent unethical trade and commercial practices. 8. Maintain the dignity and reputation of the pharmacy profession. 9. Encourage pharmacists to maintain competence and professional knowledge. 10. Ensure compliance with applicable pharmacy and drug laws. 2.1.3 Key principles that guide professional Ethics in pharmaceutical jurisprudence include Integrity and Honesty: Acting with integrity and honesty, avoiding conflicts of interest, and maintaining transparency in all professional interactions. Respect for Patient Autonomy: Respecting the autonomy, dignity, and rights of patients, including informed consent, privacy, and confidentiality. Patient Welfare and Safety: Prioritizing the well-being and safety of patients, ensuring the quality, safety, and efficacy of

pharmaceutical products, and promoting evidence-based practice. Compliance with Laws and Regulations: Adhering to pharmaceutical legislation, regulations, and codes of conduct to ensure legal compliance and ethical behavior. Ethical Research and Innovation: Conducting pharmaceutical research with integrity, respecting the rights and welfare of research participants, and ensuring the responsible and ethical development and use of new pharmaceutical products. Professional Competence: Maintaining and enhancing professional competence through continuous education, training, and staying updated with advancements in pharmaceutical jurisprudence. Collaboration and interprofessional: Collaborating with other healthcare professionals, regulatory authorities, policymakers, and stakeholders to promote patient-centered care, interprofessional collaboration, and public health. Social Responsibility: Recognizing and addressing the broader social implications of pharmaceutical practices, advocating for equitable access to medicines, and contributing to the well- being of individuals and communities.

The pharmaceutical code of ethics serves as a guide to foster responsible behavior, maintain the integrity of the industry, and uphold public trust. It helps to ensure that pharmaceutical professionals and organizations operate ethically, to improve patient care, advance public health, and promote the well-being of society. In terms of values and temperament, the pharmaceutical profession is honorable. The attitude of service and sacrifice in the interests of the suffering humanity is ingrained in this profession in addition to being a means of generating a living. In addition to other arduous duties, a pharmacist is responsible for protecting people's health when handling, selling, distributing, compounding, and dispensing medical chemicals, such as poisons and strong medications. He is therefore required to put his patrons' interests above all else. As a result, he must put his patrons' interests above anything else. All

chemists should fervently uphold the noble standards established by Charaka, an ancient philosopher, physician, and pharmacist, who said: "Even if your own life be in danger, you should not betray or neglect the interests of your patients." The government limits those who meet the necessary qualifications to practice pharmacy and grants them privileges that must be withheld from others. In exchange, the government anticipates that the chemist will be aware of his tasks and fulfill them honorably and with due consideration for society's well-being. In the public's best interest, pharmacy professional conduct standards are required to provide effective pharmaceutical services. Every chemist should be willing to contribute to the provision of such a service, but they should also refrain from any action or inaction that would compromise the provision of the services or undermine faith in pharmacists as a group. The demands of pharmaceutical practice may be too great for an individual to handle, or to handle as fast or efficiently as the needs of the general population demand. Therefore, there should always be a willingness to provide information or advice to coworkers. Above all, a chemist must be a good citizen who upholds and defends the laws of both the state and the country.

DID YOU KNOW ? The concept of professional ethics has ancient roots, dating back to the Hippocratic Oath taken by physicians in ancient Greece, which emphasized ethical principles such as patient confidentiality, beneficence, and non-maleficence. This oath laid foundational ethical standards that continue to influence medical ethics today. 2.2 PHARMACISTS IN RELATION TO THE JOB SCOPE OF PHARMACEUTICAL SERVICE A sufficiently full pharmaceutical service ought to be offered when a location is opened as a pharmacy and registered by legal criteria. This entails the prompt supply of such commonly needed medications. It also requires a readiness to always have emergency supplies available. 2.2.1 Conduct of the Pharmacy: When preparing, administering, and supplying medicines, a pharmacy's environment should be such as to eliminate any unnecessary danger, mistake, or inadvertent contamination.

• The setting should convey the pharmacy's professional demeanor. Public awareness of the establishment's pharmacy practice should be high. The size, design, and language of all signs, notices, descriptions, wording on business stationery, and other associated signals should be controlled. • Descriptions that indicate or suggest pharmacological qualifications should be restricted to those for whom the usage is prohibited by law and should not unfairly differentiate between chemists. • Dispensing under the Employees State Insurance Scheme (ESIS) or any other government-sponsored scheme may be carried out, according to a notice that may be shown on the property. • Every pharmacy should have a chemist in charge who will be held principally accountable for upholding appropriate standards of behavior in the pharmacy. • Any interference by the owner with the chemist's performance of his duties in this regard would be viewed as a failure on the part of the owner to uphold the relevant standards.

2.2.2 Handling of Prescriptions: When a prescription is made available for dispensing, a chemist should accept it without questioning or commenting on its medicinal value. After obtaining a prescription, the chemist should not show any physiognomic signals of fear or surprise since doing so may cause patients or their representatives to become nervous and lose trust in their doctor. Answers to prescription-related queries should be addressed with care and deliberation; they should not anger a client or divulge any information that was purposely hidden from him. • A chemist is not permitted to modify the composition of a

prescription or add, remove, or substitute any substances without the prescriber's authorization unless the modification is urgent or strictly essential for the practice of pharmacy and has no effect on the recipe's therapeutic effectiveness. If there is an evident error in the prescription due to an omission, incompatibility, or over dosage, it should be returned to the doctor for correction or approval of the proposed modification. While such an act is important for the patient's benefit, it should never be performed in a way that jeopardizes the prescriber's image. • A pharmacist should rigorously follow the prescriber's instructions while refilling prescriptions, and he should advise patients to use medications or treatments exclusively for the purposes mentioned on the prescription. 2.2.3 Purchase of Drugs: Medicines should be purchased from genuine and reputable sources. A pharmacist should not knowingly participate in the manufacture, purchase, possession, distribution or sale of spurious or substandard medicines. 2.2.4 Storage of Medicines The pharmacist should ensure: 1. Appropriate storage conditions. 2. Proper temperature and environmental control where required. 3. Protection from contamination. 4. Proper segregation of medicines. 5. Appropriate stock rotation.

Safe custody of controlled or restricted medicines. 2.2.5 Dispensing The pharmacist should exercise professional care while dispensing medicines. Particular attention should be given to: 1. Correct medicine. 2. Correct strength. 3. Correct quantity. 4. Correct label. 5. Correct patient. 6. Appropriate directions for use. Identification of possible dispensing errors. 2.3 PHARMACIST IN RELATION TO HIS TRADE Pharmacy is a profession as well as a commercial activity, but commercial considerations should not compromise patient safety. A pharmacist should: 1. Deal honestly with customers. 2. Avoid misleading claims regarding medicines. 3. Avoid adulterated, spurious or substandard products. 4. Purchase medicines from legitimate sources. 5. Maintain appropriate records. 6. Avoid unethical competition.

7. Avoid practices that encourage unnecessary self- medication. 8. Maintain professional standards in advertisements and displays. The Code specifically discourages hawking of drugs and emphasizes professional supervision in pharmaceutical services. 2.3.1 Pharmacist in Relation to Medical Profession The pharmacist is an important member of the healthcare team. A pharmacist should: 1. Maintain professional relationships with medical practitioners. 2. Respect the professional responsibilities of other healthcare professionals. 3. Assist physicians and other healthcare professionals with appropriate pharmaceutical information. 4. Clarify prescriptions when genuine doubts arise. 5. Avoid criticizing another healthcare professional in front of patients. 6. Cooperate in promoting safe and rational use of medicines. 7. Maintain confidentiality of information obtained through professional practice. The pharmacist should act as a healthcare professional rather than merely as a seller of medicines. 2.3.2 Pharmacist in Relation to Patients: The patient's welfare should be a primary consideration in pharmaceutical practice.

A pharmacist should: a) Maintain confidentiality: Information obtained about a patient's condition, medication or personal circumstances during professional practice should be kept confidential, except where disclosure is required by law. b) Provide counselling Where appropriate, the pharmacist should explain: 1. How to use the medicine. 2. Dose and frequency. 3. Route of administration. 4. Important precautions. 5. Storage requirements. 6. Relevant instructions given with the prescription. 2.3.3 Avoid discrimination: Pharmaceutical services should be provided professionally and respectfully without unfair discrimination. 2.3.4 Promote patient safety: The pharmacist should take reasonable steps to identify and prevent: 1. Wrong medicines. 2. Wrong strength. 3. Wrong quantity. 4. Labelling errors. 5. Drug-related problems. 6. Unsafe storage.

7. Potentially inappropriate medication use. 2.4 PHARMACIST IN RELATION TO HIS PROFESSION A pharmacist has a responsibility to maintain the dignity and reputation of the profession. He/she should: • Maintain high standards of professional conduct. • Continue professional education. • Keep knowledge and skills up to date. • Support legitimate professional organizations. • Cooperate with fellow pharmacists. • Assist colleagues with professional information when appropriate. • Avoid conduct that brings the profession into disrepute. The PCI emphasizes professional education, competence and high standards of professional conduct as important elements of pharmacy practice. 2.4.1 Relationship with Fellow Pharmacists A pharmacist should maintain professional courtesy and cooperation with colleagues. He/she should:

• Respect the professional status of other pharmacists. • Share appropriate professional knowledge. • Assist colleagues when necessary. • Avoid unfair practices intended to damage another pharmacist's professional reputation. • Resolve professional disagreements respectfully. • Promote the collective advancement of pharmacy. 2.4.2 Professional Competence and Continuing Education A pharmacist should continually improve professional knowledge and skills. This includes keeping updated regarding: • New medicines. • Drug information. • Dosage forms. • Drug interactions. • Adverse drug reactions. • Storage requirements. • Dispensing procedures. • Pharmaceutical legislation. • Patient counselling. • Developments in pharmacy practice. The Pharmacist's Oath also emphasizes enlarging pharmaceutical knowledge for the advancement of pharmacy and public health. 2.4.3 Confidentiality

Confidentiality is an important ethical responsibility. A pharmacist should not disclose information concerning: • Patient identity. • Disease or health condition. • Prescription. • Medication history. • Personal information. • Information obtained during professional practice. Disclosure may be made when required or permitted by law or when otherwise professionally justified. The PCI Pharmacist's Oath explicitly includes maintaining confidentiality of knowledge gained about patients through professional practice. 2.4.4 Ethical Advertising and Promotion Pharmaceutical advertising and promotion should be: • Truthful. • Responsible. • Professional. • Non-misleading. • Consistent with applicable laws and regulations. For pharmaceutical companies, India's Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 establishes ethical requirements for promotion and interactions

with healthcare professionals, including restrictions concerning gifts, monetary benefits and hospitality. 2.4.5 Pharmacist's Oath The Pharmacist's Oath adopted in Indian pharmacy education expresses commitments including: • Upholding laws and professional standards. • Serving as an integral part of the healthcare team. • Continuously improving pharmaceutical knowledge. • Providing appropriate pharmaceutical care and counselling. • Contributing to pharmaceutical advancement and public health. • Maintaining patient confidentiality. • Supporting organizations working for the advancement of pharmacy.

2.5 SIGNIFICANCE OF PROFESSIONAL ETHICS Professional ethics forms the cornerstone of pharmaceutical jurisprudence, guiding the conduct and decision-making processes of professionals within the pharmaceutical industry. These ethical principles are crucial for maintaining public trust, ensuring the integrity of the profession, and safeguarding the health and well-being of patients. This section explores the significance of professional ethics in pharmaceutical jurisprudence, highlighting its impact on legal compliance, patient safety, and professional accountability. 2.5.1 ENSURING LEGAL COMPLIANCE Professional ethics in pharmaceutical jurisprudence ensures that industry practitioners adhere to legal standards and regulations. Ethical principles act as a moral compass, guiding professionals to comply with laws governing drug development, manufacturing, distribution, and marketing. By adhering to ethical standards, pharmaceutical professionals help to: 1. Prevent Legal Infractions: Ethical guidelines reinforce the importance of complying with regulatory requirements, reducing the risk of legal violations and associated penalties.

2. Promote Transparent Practices: Ethical behavior fosters transparency in reporting clinical trial results, adverse drug reactions, and manufacturing practices, which is critical for regulatory scrutiny and public trust. 3. Support Regulatory Frameworks: By adhering to ethical standards, professionals contribute to the development and enforcement of robust regulatory frameworks that protect public health. 2.5.2 SAFEGUARDING PATIENT SAFETY The primary objective of pharmaceutical ethics is to ensure patient safety and well-being. Ethical principles guide professionals to prioritize the health of patients above commercial interests, ensuring that: 1. Safety Standards Are Upheld: Adherence to ethical practices ensures that drugs and medical products meet rigorous safety standards before reaching the market. 2. Informed Consent Is Obtained: Ethical guidelines mandate that patients are fully informed about the benefits and risks of treatments, ensuring that consent is obtained freely and without coercion. 3. Quality Control Is Maintained: Ethical obligations compel professionals to maintain high standards of quality control throughout the drug development and manufacturing processes, minimizing the risk of harm to patients.

2.5.3 FOSTERING PROFESSIONAL ACCOUNTABILITY Ethics in pharmaceutical jurisprudence promotes accountability among professionals, ensuring that they act responsibly and with integrity. This accountability is crucial for maintaining the credibility and trustworthiness of the profession. Key aspects include: 1. Responsibility to Stakeholders: Ethical standards require professionals to act responsibly towards all stakeholders, including patients, healthcare providers, regulatory bodies, and society at large. 2. Integrity in Research and Development: Upholding ethical principles ensures that pharmaceutical research and development are conducted with honesty and integrity, avoiding practices such as data falsification or plagiarism. 3. Commitment to Continuous Improvement: Ethical obligations encourage professionals to engage in lifelong learning and continuous improvement, ensuring that they stay updated with the latest advancements and best practices in the field. 2.5.4 ENHANCING PUBLIC TRUST Public trust is essential for the pharmaceutical industry, and ethical practices play a crucial role in building and maintaining this trust. Ethical conduct by pharmaceutical professionals ensures that:

1. Confidence in Pharmaceutical Products: Ethical practices in drug development, testing, and marketing build public confidence in the safety and efficacy of pharmaceutical products. 2. Transparency and Honesty: Ethical behavior promotes transparency and honesty in interactions with the public, fostering an environment of trust and reliability. 3. Reputation Management: Upholding high ethical standards helps protect the reputation of the pharmaceutical industry, reducing the risk of scandals and public distrust. Professional ethics is integral to pharmaceutical jurisprudence, serving as a foundation for legal compliance, patient safety, professional accountability, and public trust. By adhering to ethical principles, pharmaceutical professionals not only fulfill their legal obligations but also contribute to the overall integrity and reliability of the industry. In an era where public scrutiny and regulatory expectations are continually increasing, the significance of professional ethics cannot be overstated. It is the bedrock upon which the trust and credibility of the pharmaceutical profession are built and maintained. Let’s Revise! • Professional ethics in pharmaceutical jurisprudence refers to the set of moral principles and values that guide the conduct and behavior of individuals and organizations

involved in the pharmaceutical industry within the legal framework. • The pharmaceutical code of ethics serves as a framework to ensure that the industry operates ethically and responsibly, upholds patient welfare, maintains integrity, and builds trust with stakeholders. • Key principles that guide professional ethics in pharmaceutical jurisprudence include: a) Integrity and Honesty b) Respect for Patient Autonomy c) Patient Welfare and Safety d) Compliance with Laws and Regulations e) Ethical Research and Innovation f) Professional Competence g) Collaboration and interprofessional h) Social Responsibility • A sufficiently full pharmaceutical service ought to be offered when a location is opened as a pharmacy and registered by legal criteria. • When preparing, administering, and supplying medicines, a pharmacy's environment should be such as to eliminate any unnecessary danger, mistake, or inadvertent contamination.

• When a prescription is made available for dispensing, a chemist should accept it without questioning or commenting on its medicinal value. • Professional ethics forms the cornerstone of pharmaceutical jurisprudence, guiding the conduct and decision-making processes of professionals within the pharmaceutical industry. 1. What do you mean by professional ethics? Give its significance. 2. Describe the ethics that a pharmacist should have with his job. 3. Describe the Pharmacist’s Oath. 4. Explain the key principles that guide professional ethics in pharmaceutical jurisprudence.

C H A P T E R - 3

C H A P T E R - 3 THE DRUG AND COSMETIC ACT, 1940 LEARNING OBJECTIVE ➢ To study the Drug and Cosmetics Act and the rules thereunder ➢ To study the retail and wholesale distribution of the drug ➢ To study the power of inspectors, the sampling procedures, and the procedural formalities in obtaining licenses under the rule ➢ To understand the facilities of a pharmacy ➢ To study the Schedules and their special references: C, CI, F, G, J, H, P, and X ➢ To study the salient features of the labeling and storage condition of drugs The Drugs and Cosmetics Act, 1940 is an Act of the Parliament of India which regulates the import, manufacture, distribution, and sale of drugs and cosmetics. The primary objective of this Act is to ensure that the drugs and cosmetics sold in India are safe, effective, and conform to quality standards.

3.1 OVERVIEW OF DRUG AND COSMETIC ACT The Drugs and Cosmetics Act, 1940, along with the rules framed thereunder, provides a comprehensive legal framework for regulating the pharmaceutical and cosmetic industries in India. The Act is divided into several chapters and sections that address various aspects of drug and cosmetic regulation. 3.1.1 KEY SECTIONS OF THE ACT: 1. Title, Extent, and Commencement (Section 1): • The Act may be called the Drugs and Cosmetics Act, 1940. • It extends to the whole of India. • It shall come into force on such date as the Central Government may, by notification in the Official Gazette, appoint. 2. Definitions (Section 3): • This section provides definitions for various terms used in the Act, such as "drug," "cosmetic," "manufacture," "import," and others. 3. Regulation of Import, Manufacture, and Sale of Drugs and Cosmetics (Sections 10 to 18): • Section 10: Prohibits the import of certain drugs and cosmetics. • Section 12: Provides the procedure for import registration.

• Section 18: Prohibits the manufacture and sale of certain drugs and cosmetics unless they comply with prescribed standards. 4. Licensing (Sections 18A to 18C): • Requires manufacturers and sellers to obtain licenses for manufacturing, selling, or distributing drugs and cosmetics. 5. Labelling and Packaging (Section 17 and 17A): • Mandates proper labelling and packaging of drugs and cosmetics to ensure consumer safety. 6. Authorities (Sections 21 to 26A): • Establishes various authorities for the enforcement of the Act, such as Drug Inspectors, Government Analysts, and the Central Drugs Laboratory. 7. Penalties (Sections 27 to 31A): • Specifies penalties for violations of the Act, including imprisonment and fines. 8. Miscellaneous (Sections 32 to 38): • Includes provisions for legal proceedings, protection of action taken in good faith, and power to make rules. 3.1.2 RULES UNDER THE ACT: The Act is supplemented by the Drugs and Cosmetics Rules, 1945, which provide detailed regulations for implementing the

provisions of the Act. Some key areas covered by the Rules include: 1. Standards for Drugs and Cosmetics: • Specifies the standards for the quality, purity, and strength of drugs and cosmetics. 2. Requirements for Licensing: • Details the procedures and requirements for obtaining licenses to manufacture, sell, or distribute drugs and cosmetics. 3. Labelling and Packaging: • Prescribes the manner in which drugs and cosmetics must be labelled and packaged. 4. Good Manufacturing Practices (GMP): • Lays down guidelines for maintaining quality control and ensuring good manufacturing practices in the pharmaceutical and cosmetic industries. 5. Clinical Trials and New Drugs: • Regulates the conduct of clinical trials and the approval process for new drugs. 6. Regulation of Schedule Drugs: • Lists specific drugs and their regulations under various schedules (e.g., Schedule H, Schedule X).

The Drugs and Cosmetics Act, 1940, along with its rules, plays a crucial role in ensuring the safety, efficacy, and quality of drugs and cosmetics in India. Understanding the provisions of this Act is essential for professionals involved in the pharmaceutical and cosmetic industries, as well as for regulatory authorities responsible for enforcing these regulations. 3.2 THE RETAIL AND WHOLESALE DISTRIBUTION OF DRUGS The retail and wholesale distribution of drugs in India is regulated under the Drugs and Cosmetics Act, 1940, and its accompanying rules. This section outlines the legal framework governing the distribution channels, ensuring the availability of safe and effective drugs to the public while maintaining stringent control over the distribution process. KEY PROVISIONS GOVERNING RETAIL AND WHOLESALE DISTRIBUTION: 1. Licensing Requirements: • Section 18(c): Prohibits the manufacture, sale, or distribution of drugs except under and in accordance with the conditions of a license issued under the Act. • Retail and wholesale dealers must obtain licenses from the appropriate authority. These licenses are categorized into different forms based on the type of drugs (e.g., Form 20, Form 21 for retail; Form 20B, Form 21B for wholesale).

2. Qualification of License Holders: • Retail drug sales must be supervised by a registered pharmacist or a competent person approved by the licensing authority. • Wholesale drug distributors must employ competent technical staff to ensure compliance with the regulations. 3. Storage and Premises: • Retail and wholesale outlets must maintain proper storage conditions to preserve the efficacy and safety of drugs. • The premises must comply with the standards prescribed by the Act and rules, ensuring hygienic conditions and adequate space for storage. 4. Labeling and Packaging: • All drugs must be labeled and packaged in accordance with the requirements specified in the Act. This includes proper labeling of the drug’s name, dosage, batch number, manufacture and expiry dates, and storage conditions. • Retailers must ensure that drugs are sold in their original packaging to preventtampering. 5. Record Keeping and Reporting: • Retail and wholesale distributors must maintain accurate records of all transactions, including purchases and sales. These records should include details such as the name of the drug, quantity, batch number, supplier’s details, and the date of the transaction. • Periodic reports may be required to be submitted to the regulatory authorities to ensure compliance and traceability.

6. Inspection and Compliance: • Drug Inspectors are authorized to inspect premises where drugs are stored, sold, or distributed to ensure compliance with the Act and rules. • Non-compliance with the regulations can lead to suspension or cancellation of the license, and in severe cases, legal action against the license holder. 7. Sale of Schedule Drugs: • Certain drugs listed under specific schedules (e.g., Schedule H, Schedule X) have additional restrictions on their sale. These drugs can only be sold on the prescription of a registered medical practitioner and must be dispensed by a licensed pharmacist. • Retailers must retain the prescriptions for a specified period and make them available for inspection by authorities. 8. Prohibition of Certain Sales: • The sale of drugs that are misbranded, adulterated, or spurious is strictly prohibited. • Retailers and wholesalers must ensure that they source drugs only from licensed manufacturers and distributors to prevent the circulation of substandard drugs. The regulation of retail and wholesale distribution of drugs under the Drugs and Cosmetics Act, 1940, ensures that drugs reaching consumers are safe, effective, and of high quality. Adherence to the licensing requirements, proper storage, accurate record-keeping, and compliance with labeling and packaging norms are critical components of this regulatory

framework. By understanding and following these provisions, distributors can contribute to public health and safety. DID YOU KNOW ? The Drug & Cosmetic Act, 1940 was influenced by the United States Food, Drug, and Cosmetic Act of 1938, reflecting the global trends in drug regulation during that era. 3.3 THE POWER OF INSPECTORS The Drugs and Cosmetics Act, 1940, and the rules framed thereunder empower inspectors to enforce the Act’s provisions,

outline sampling procedures for drugs and cosmetics, and stipulate the procedural formalities for obtaining various licenses. This section provides a detailed overview of these aspects. 3.3.1 THE POWER OF INSPECTORS: 1. Appointment of Inspectors (Section 21): • The Act allows for the appointment of Inspectors by the Central Government or State Government to oversee the enforcement of the Act and its rules. 2. Powers of Inspectors (Section 22): • Inspection of Premises: Inspectors can inspect premises where drugs or cosmetics are manufactured, stored, or sold. • Sample Collection: They can take samples of any drug or cosmetic to ascertain if they comply with the Act's standards. • Examination of Records: Inspectors have the authority to examine and seize records, registers, and documents relating to the manufacture, storage, or sale of drugs or cosmetics. • Search and Seizure: They can enter and search premises, and seize any drug or cosmetic that appears to be in contravention of the Act. • Prohibition Orders: Inspectors can issue orders to stop the manufacture, sale, or distribution of drugs or cosmetics that are found to be substandard, adulterated, or misbranded.

3. Obligations of Persons: • The Act requires persons in charge of premises to provide necessary assistance to inspectors and comply with their requests during inspections and investigations. 3.3.2 SAMPLING PROCEDURES: 1. Collection of Samples (Section 23): • Inspectors are authorized to take samples of drugs or cosmetics for analysis. The sampling procedure involves: ➢ Drawing a representative sample in the presence of the owner or representative of the premises. ➢ Dividing the sample into four portions, sealing, and marking them. ➢ Delivering one portion to the owner, sending another to the Government Analyst, retaining one for future reference, and submitting one to the court if needed. 2. Analysis by Government Analyst (Section 25): • The Government Analyst is responsible for analyzing the samples and submitting a report on whether the drug or cosmetic complies with the prescribed standards. • The report of the Government Analyst is considered evidence of the facts stated therein unless challenged. 3. Procedures in Case of Non-Compliance:

• If the sample fails to meet the standards, the Inspector can take further action, including prosecution of the manufacturer or distributor, and issuing prohibition orders. 3.3.3 PROCEDURAL FORMALITIES IN OBTAINING LICENSES: 1. Application for License: • Forms and Documentation: Applicants must submit an application in the prescribed form along with required documents such as proof of premises, qualifications of technical staff, and details of equipment. • Fees: Payment of the requisite fee is mandatory for processing the license application. 2. Inspection of Premises: • The licensing authority may direct an inspection of the premises by an Inspector to verify compliance with the requirements before granting a license. 3. Grant of License: • Conditions: Licenses are granted subject to conditions related to the maintenance of proper storage conditions, record-keeping, and compliance with labeling and packaging norms. • Validity and Renewal: Licenses are typically valid for a specified period and must be renewed periodically. Renewal applications should be submitted before the expiry of the existing license.

4. Refusal and Cancellation of License: • The licensing authority can refuse to grant or renew a license if the applicant fails to comply with the prescribed standards. • Licenses can be suspended or canceled if the licensee is found to be in violation of the Act or rules, after giving an opportunity to be heard. 5. Appeals: • Applicants or licensees aggrieved by the decision of the licensing authority can file an appeal to the State Government or Central Government, as applicable. The powers of inspectors, the sampling procedures, and the procedural formalities in obtaining licenses under the Drugs and Cosmetics Act, 1940, and its rules ensure that drugs and cosmetics distributed in India meet the required safety and quality standards. These provisions are crucial for maintaining public health and ensuring compliance within the pharmaceutical and cosmetic industries. 3.4 THE FACILITIES OF A PHARMACY The Drugs and Cosmetics Act, 1940, along with the rules framed under it, specifies the standards and facilities that a pharmacy must maintain to ensure the safe and effective storage, handling, and distribution of drugs and cosmetics.

These facilities are crucial for maintaining the quality of pharmaceutical products and for safeguarding public health. KEY FACILITIES OF A PHARMACY: 1. Physical Premises: • Location and Size: The pharmacy should be situated in a suitable location and have adequate space for the storage and display of drugs and cosmetics. The premises must comply with the size requirements specified by the regulatory authorities. • Clean and Hygienic Environment: The pharmacy should maintain cleanliness and hygiene to prevent contamination of drugs. This includes regular cleaning and proper waste disposal. 2. Storage Facilities: • Shelving and Organization: Drugs must be stored on shelves, racks, or cabinets in an organized manner to prevent mix-ups and ensure easy access. Proper labeling and segregation of different types of drugs are essential. • Temperature Control: Certain drugs require specific temperature conditions for storage. The pharmacy must have facilities such as refrigerators or air-conditioned storage areas to maintain the required temperatures.

• Humidity Control: For drugs sensitive to moisture, the pharmacy should have humidity control measures in place, such as dehumidifiers or moisture-proof packaging. 3. Safety and Security: • Security Systems: To prevent theft or unauthorized access, the pharmacy should have secure locks, surveillance cameras, and alarm systems. Controlled substances must be stored in a secure manner, often in locked cabinets or safes. • Fire Safety: The pharmacy should be equipped with fire safety equipment, such as fire extinguishers and smoke detectors, and have clear evacuation plans in case of emergencies. 4. Dispensing Area: • Prescription Area: A designated area for receiving and processing prescriptions should be available. This area should have facilities for checking prescriptions, preparing medications, and counseling patients. • Seating and Waiting Area: Adequate seating arrangements for patients waiting to receive their medications should be provided. 5. Equipment and Supplies: • Dispensing Tools: The pharmacy must have appropriate tools and equipment for dispensing medications, such as pill counters, measuring cylinders, mortars and pestles, and labeling machines.

• Packaging Materials: Adequate supplies of packaging materials, including vials, bottles, blister packs, and labels, should be available to ensure proper dispensing and labeling of drugs. 6. Qualified Personnel: • Registered Pharmacists: The pharmacy must employ registered pharmacists who are qualified and licensed to dispense medications and counsel patients. The presence of a registered pharmacist during operating hours is mandatory. • Support Staff: Trained support staff, such as pharmacy technicians and assistants, should be available to assist with the operations of the pharmacy. 7. Record Keeping: • Transaction Records: Accurate records of all transactions, including details of drugs received and dispensed, should be maintained. This includes maintaining a register for prescription medications. • Inventory Management: Regular inventory checks and proper documentation of stock levels, batch numbers, and expiry dates are essential for effective inventory management and to prevent stockouts or overstocking. 8. Patient Counseling Area: • Private Counseling Space: A separate area for private patient counseling should be available, allowing

pharmacists to discuss medications, usage instructions, and potential side effects with patients confidentially. • Educational Materials: The pharmacy should provide educational materials, such as pamphlets, brochures, and posters, to inform patients about various health conditions and the proper use of medications. 9. Compliance with Regulations: • Adherence to Standards: The pharmacy must comply with all relevant regulations and standards set by the Drugs and Cosmetics Act, 1940, and the Pharmacy Act, 1948. This includes obtaining and renewing necessary licenses and certifications. • Audit and Inspection Readiness: The pharmacy should be prepared for regular inspections and audits by regulatory authorities to ensure ongoing compliance with legal requirements. The facilities of a pharmacy, as outlined under the Drugs and Cosmetics Act, 1940, are designed to ensure that drugs and cosmetics are stored, handled, and dispensed in a safe and effective manner. By maintaining the required standards and facilities, pharmacies play a critical role in safeguarding public health and ensuring the quality and efficacy of pharmaceutical products. 3.5 THE SCHEDULES AND THEIR SPECIAL REFERENCES

The Drugs and Cosmetics Act, 1940, and the rules framed under it categorize various drugs and substances into different schedules. Each schedule specifies unique regulatory requirements for manufacturing, storage, sale, and distribution. Below is an overview of the key schedules and their special references. SCHEDULE C AND C1: • Schedule C: Biological and special products including sera, vaccines, toxins, antitoxins, insulin, bacteriophages, blood products, and similar biological products. • Schedule C1: Extends the coverage of Schedule C to additional biological products such as drugs specified for the prevention or treatment of specific diseases. • Special References: ➢ Rigorous standards for manufacturing, testing, and storage. ➢ Special packaging and labeling requirements. ➢ Periodic quality control and testing by government laboratories. 3.5.1 SCHEDULE F: • Schedule F: Specifies standards for blood and blood products, including collection, storage, processing, and distribution. • Special References: ➢ Detailed guidelines for blood banks and transfusion services.

➢ Requirements for donor selection, blood collection, and storage. ➢ Standards for testing blood for transmissible diseases. 3.5.2 SCHEDULE G: • Schedule G: Lists drugs that must be sold under medical supervision and labeled with the caution "Caution: It is dangerous to take this preparation except under medical supervision." • Special References: ➢ Drugs requiring strict medical supervision due to the potential for side effects or misuse. ➢ Labeling must include clear warnings to ensure patient safety. 3.5.3 SCHEDULE H: • Schedule H: Contains a list of prescription drugs that can only be sold on the prescription of a registered medical practitioner. • Special References: ➢ These drugs cannot be sold without a valid prescription. ➢ Labeling must include "Rx" symbol and the warning "Schedule H drug. Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only." ➢ Ensures control over the sale and distribution of potentially hazardous drugs. 3.5.4 SCHEDULE J:

• Schedule J: Lists diseases and conditions for which drugs cannot claim to cure or prevent, reflecting the prohibition of misleading advertisements. • Special References: ➢ Includes serious conditions like cancer, diabetes, AIDS, and others where false claims of cure are prohibited. ➢ Prevents exploitation of patients by prohibiting false and exaggerated therapeutic claims. 3.5.5 SCHEDULE P: • Schedule P: Specifies the life period (shelf life) of drugs, indicating the time during which a drug can be expected to retain its potency and safety. • Special References: ➢ Defines storage conditions and expiration periods for various drugs. ➢ Ensures that expired or sub-potent drugs are not available to consumers. 3.5.6 SCHEDULE X: • Schedule X: Lists narcotic and psychotropic substances that require stringent control due to their potential for abuse and addiction. • Special References: ➢ These drugs have additional restrictions on manufacture, storage, sale, and distribution. ➢ Must be stored in a locked and secure place. ➢ Record-keeping and stringent documentation requirements for transactions.

➢ Labeling must include the warning "Schedule X drug. Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only." The Schedules under the Drugs and Cosmetics Act, 1940, play a critical role in regulating the pharmaceutical and cosmetic industries in India. Each schedule addresses specific categories of drugs and substances, providing tailored regulatory requirements to ensure their safe and effective use. By understanding and complying with these schedules, manufacturers, distributors, and healthcare professionals can help safeguard public health and ensure the quality and efficacy of drugs and cosmetics.

3.6 THE SALIENT FEATURES OF THE LABELING AND STORAGE The Drugs and Cosmetics Act, 1940, along with the rules framed under it, provides detailed regulations regarding the labeling and storage conditions of drugs to ensure their safety, efficacy, and quality. These regulations are crucial for protecting public health and ensuring that consumers receive drugs that are both effective and safe to use. 3.6.1 SALIENT FEATURES OF LABELING OF DRUGS: 1. Mandatory Information on Labels: • Name of the Drug: The label must clearly display the name of the drug, both its generic and brand names. • Dosage Form and Strength: Information about the dosage form (e.g., tablet, syrup) and the strength of the drug (e.g., 500 mg) must be included. • Batch Number: The label must include the batch number, which helps in tracking and recalling products if necessary. • Manufacturing and Expiry Dates: The dates of manufacture and expiry must be clearly mentioned to ensure the drug is used within its shelf life. • Manufacturer’s Details: The name and address of the manufacturer, packer, or distributor must be provided.

2. Special Labeling Requirements: • Prescription Drugs (Schedule H and X): Must include the caution "To be sold by retail on the prescription of a Registered Medical Practitioner only" and bear the "Rx" symbol. • Biological Products (Schedule C and C1): Must include the statement "Keep out of reach of children" and special storage instructions if required. • External Use Drugs: Must be labeled with "For external use only." 3. Warnings and Precautions: • Labels must include any necessary warnings, precautions, and contraindications to ensure the safe use of the drug. For example, "Caution: It is dangerous to take this preparation except under medical supervision" for Schedule G drugs. • Specific instructions for use, such as "Shake well before use" or "Store in a cool, dry place," must be provided. 4. Exemptions and Exceptions: • Certain drugs may be exempted from specific labeling requirements under special conditions prescribed by the regulatory authorities. 5. Tamper-Evident Packaging: • Drugs must be packaged in tamper-evident containers to ensure that they have not been altered or contaminated.

6. Barcodes and QR Codes: • Increasingly, labels may include barcodes or QR codes to enable tracking and verification of drug authenticity. 3.6.2 SALIENT FEATURES OF STORAGE CONDITIONS OF DRUGS: 1. Temperature Control: • Room Temperature: Drugs that can be stored at room temperature should be kept in a controlled environment, typically between 15°C to 25°C. • Refrigerated Storage: Drugs requiring refrigeration should be stored at temperatures between 2°C to 8°C. • Frozen Storage: Certain drugs need to be stored in a freezer at temperatures below -20°C.

2. Humidity Control: • Drugs sensitive to moisture should be stored in dry conditions with controlled humidity levels to prevent degradation. 3. Light Protection: • Drugs that are sensitive to light should be stored in opaque or amber-colored containers to protect them from light exposure. 4. Security Measures: • Controlled Substances (Schedule X): Must be stored in a locked, secure area with restricted access to prevent misuse and theft. • Narcotics and Psychotropics: Additional security measures, including surveillance and inventory controls, are required. 5. Segregation of Different Types of Drugs: • Proper segregation of drugs is necessary to avoid cross- contamination and mix-ups. For example, drugs for internal use should be stored separately from those for external use. 6. Handling and Disposal: • Procedures for the safe handling and disposal of drugs, especially those that are hazardous or have expired, must be in place. 7. Stock Rotation: • Implementing a first-expiry-first-out (FEFO) system ensures that drugs are used in the order of their expiry dates to minimize waste and ensure efficacy.

8. Monitoring and Maintenance: • Regular monitoring of storage conditions, including temperature and humidity, is necessary. Maintenance of storage equipment, such as refrigerators and freezers, is also critical. The labeling and storage conditions of drugs as prescribed by the Drugs and Cosmetics Act, 1940, are essential for ensuring the safety, efficacy, and quality of pharmaceutical products. Adherence to these regulations helps prevent medication errors, protects consumers from harmful substances, and maintains the integrity of the drug supply chain. By following these guidelines, manufacturers, distributors, and pharmacies can ensure that drugs are stored and labeled properly, thereby safeguarding public health. Let’s revise! • Overview of the Act: ➢ Legislation governing drugs and cosmetics in India. ➢ Regulates import, manufacture, distribution, and sale of drugs and cosmetics. • Wholesale Distribution: ➢ Defines rules for the retail and wholesale distribution channels. ➢ Specifies licensing requirements for distributors.

• Powers of Inspectors: ➢ Inspectors empowered to enforce compliance with the Act. ➢ Authority to inspect premises, seize adulterated drugs, and initiate legal action. • Sampling Procedures: ➢ Procedures for sampling drugs to ensure quality and safety. ➢ Samples analyzed to verify compliance with standards. • Licensing Procedures: ➢ Requirements and procedures for obtaining licenses. ➢ Different categories of licenses based on activities (manufacture, sale, distribution). • Pharmacy Facilities: ➢ Standards for facilities where drugs are stored and handled. Requirements for maintaining hygiene and safety. a) Schedules (C, CI, F, G, J, H, P, X): ➢ Classification of drugs and cosmetics based on their potential for abuse, therapeutic use, and safety. ➢ Each schedule dictates regulations for manufacturing, sale, and distribution. • Labeling Features: ➢ Requirements for labeling drugs and cosmetics.

➢ Information on labels includes composition, dosage, precautions, and expiry date. • Storage Conditions: ➢ Guidelines for storing drugs and cosmetics to maintain potency and safety. ➢ Conditions ensure effectiveness and prevent degradation 1. What are the key regulations governing the retail and wholesale distribution of drugs under the Drug and Cosmetics Act, 1940? 2. Describe the powers granted to inspectors under the Drug and Cosmetics Act, 1940. How do sampling procedures contribute to ensuring drug quality and safety? 3. Outline the procedural formalities required for obtaining licenses under the Drug and Cosmetics Act, 1940. What are the different categories of licenses available?

4. Explain the significance of Schedules C, CI, F, G, J, H, P, and X under the Drug and Cosmetics Act, 1940. How do these schedules categorize drugs and cosmetics? 5. What are the salient features required on the labeling of drugs and cosmetics as per the Drug and Cosmetics Act, 1940? Why are storage conditions crucial for maintaining drug efficacy and safety?

C H A P T E R - 4

C H A P T E R - 4 DRUGS AND COSMETIC RULES 1945 LEARNING OBJECTIVE ➢ Concepts related to the Drugs and Cosmetics Rules, 1945. ➢ Scope, purpose and regulatory framework of the Drugs and Cosmetics Rules, 1945. ➢ Rules and provisions specifically applicable to the manufacture, sale, distribution and quality control of homoeopathic medicines. ➢ Licensing requirements for homoeopathic establishments involved in the manufacture and sale of homoeopathic medicines. ➢ Understanding of role and requirements of a Homoeopathic Chemist/qualified person in the manufacture, sale and dispensing of homoeopathic medicines. ➢ Requirements for labelling, packaging. 4.1 INTRODUCTION AND DEFINITIONS The Drugs and Cosmetics Rules, 1945 are an important set of rules governing the manufacture, distribution, sale, import, storage, labelling and quality control of drugs and cosmetics in India. They were framed under the Drugs and Cosmetics Act,

1940 to provide detailed procedures and standards for implementing the provisions of the Act. For students of Homoeopathic Pharmacy, these Rules are particularly relevant because they prescribe requirements concerning homoeopathic medicines, including their manufacture, licensing, labelling, standards, inspection and related regulatory requirements. The Rules are administered through the regulatory framework established under the Drugs and Cosmetics Act, with the Central Government, Central Drugs Standard Control Organisation (CDSCO), State Licensing Authorities and other designated authorities having specified responsibilities. The Rules contain provisions relating to different categories of drugs and cosmetics and include Schedules that prescribe specific standards, requirements, conditions and procedures. Objectives of the Drugs and Cosmetics Rules, 1945 The major objectives are to: 1. Ensure the quality, safety and efficacy of drugs and cosmetics. 2. Regulate the import, manufacture, distribution and sale of drugs and cosmetics. 3. Prescribe requirements for licensing of manufacturing and selling activities. 4. Establish requirements for labelling and packaging. 5. Prescribe standards for the manufacture and testing of drugs. 6. Regulate storage and handling of drugs. 7. Provide requirements for inspection and enforcement.

8. Establish specific requirements for different categories of drugs, including homoeopathic medicines. 9. Prevent the manufacture and sale of substandard, misbranded, adulterated or spurious drugs. 10. Protect public health by ensuring that medicines available in the market meet prescribed regulatory requirements. 4.2 RULES APPLICABLE TO HOMOEOPATHIC MEDICINES In India, Homoeopathic medicines are regulated under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. The Rules contain specific provisions dealing with the definition, manufacture, licensing, sale, labelling, quality standards, and new homoeopathic medicines. The Central Government identifies Rules 67A–67H and 85A–85I as important regulatory provisions for homoeopathic medicines. 1. Definition of Homoeopathic Medicine — Rule 2(dd) Under Rule 2(dd), “Homoeopathic medicines” include drugs: • recorded in Homoeopathic provings; • whose therapeutic efficacy has been established through long clinical experience as recorded in authoritative Homoeopathic literature of India and abroad; • prepared according to the techniques of Homoeopathic pharmacy; • including combinations of ingredients of such Homoeopathic medicines.

A medicine administered by the parenteral route is excluded from this definition. 2. Sale of Homoeopathic Medicines — Rules 67A to 67H Rule 67A — Licensing Authority The State Government appoints the Licensing Authority for the sale of Homoeopathic medicines. An application for a licence to sell, stock, exhibit or offer for sale, or distribute Homoeopathic medicines is made in Form 19-B. Rule 67C — Forms of Sale License Licenses for sale of Homoeopathic medicines are issued as: Type of license Form Retail sale Form 20-C Wholesale sale Form 20-D Rules 67D–67H These provisions deal with matters such as: • conditions of sale licences; • requirements relating to premises; • storage and inspection; • maintenance of records; • responsibilities of licensees; and • regulatory control over sale and distribution.

3. Manufacture of Homoeopathic Medicines — Rules 85A to 85I These are the principal rules specifically governing the manufacture of Homoeopathic medicines. The Government of India has identified Rules 85A–85I as the regulatory framework for licensing manufacture. Rule 85A — Licensing Authority The State Licensing Authority is responsible for granting licenses for manufacture of Homoeopathic medicines. Rule 85B — Application for Manufacturing License The manufacturer must apply to the appropriate Licensing Authority and comply with the prescribed requirements. Rule 85C — New Homoeopathic Medicine A New Homoeopathic Medicine cannot be manufactured unless it has been previously approved by the Licensing Authority. The applicant may be required to submit documentary evidence for assessment of its therapeutic efficacy, including evidence relating to the minimum proving carried out with the medicine. Rule 85D — Form of Manufacturing Licence A licence for manufacture of Homoeopathic medicines is granted in Form 25-C for the manufacture of potentised preparations from back potencies by pharmacies already licensed to sell Homoeopathic medicines by retail.

Rule 85E — Conditions for License The manufacturer must have appropriate competent technical staff. The Rules specify qualifications and experience requirements, including specified qualifications in: • Science with Chemistry, • Pharmacy, or • Homoeopathy, together with prescribed experience in manufacture of Homoeopathic medicines. The factory premises must also comply with the applicable requirements of Schedule M-I. Rules 85F–85I These provisions deal with further requirements relating to: • manufacturing operations; • inspection; • maintenance of standards; • licensing conditions; and • regulatory compliance for Homoeopathic manufacturing establishments. 4. Quality Standards The quality of Homoeopathic medicines is governed by the standards prescribed under the Drugs and Cosmetics regulatory framework. The Government has stated that Homoeopathic medicine standards are prescribed in Schedule II of the Drugs and Cosmetics Act, 1940, while pharmacopoeial standards and formulary specifications are developed through the official Homoeopathic pharmacopoeial system.

Therefore, manufacturers should ensure that medicines comply with the applicable Homoeopathic Pharmacopoeia/official standards. 5. Labelling Requirements The Rules prescribe specific requirements for the label of a Homoeopathic medicine. Important particulars include: 1. Name of the Homoeopathic medicine 2. Potency 3. Potency expressed in the applicable system, such as: o Decimal; o Centesimal; or o Millesimal. 4. Name and address of the manufacturer. 5. Manufacturing licence details where applicable. 6. Batch-related information, particularly for mother tinctures. 7. Alcohol content where applicable. 8. For medicines containing more than one ingredient, the name, potency and proportion of each ingredient must be stated on the label. 9. A Homoeopathic medicine containing a single ingredient should not bear a proprietary name on its label. Example A combination label should provide information in a manner such as: Ingredient A — 30C Ingredient B — 200C Ingredient C — 6X

with the prescribed proportions/other particulars where applicable. 6. Mother Tinctures Special labelling provisions apply to Homoeopathic mother tinctures. The label includes, among other particulars: • distinctive Batch Number; • Manufacturing License Number; and • other prescribed labelling information. The batch number must enable the manufacturing details of the particular batch to be traced. 7. Good Manufacturing Practices — Schedule M-I Manufacturing premises for Homoeopathic medicines are required to comply with the applicable requirements of Schedule M-I. Important areas include: • premises and sanitation; • suitable manufacturing areas; • equipment; • storage; • manufacturing operations; • quality control; • cleanliness; • prevention of contamination; and • appropriate documentation. The Government has specifically identified compliance with GMP requirements under Schedule M-I as part of the licensing and quality-control requirements for Homoeopathic medicines.

8. Purchase and Sale of Homoeopathic Medicines The Rules also regulate the manner in which Homoeopathic medicines may be sold. For certain medicines covered by the relevant provisions, requirements include: • purchase from a licensed manufacturer/dealer; • sale in the prescribed/original sealed packing where applicable; • maintenance of purchase and sale records; • prescribed labelling; and • appropriate storage. For example, certain Homoeopathic medicines covered by Schedule K provisions are subject to specific conditions concerning original sealed packing, licensed sources, separate storage from allopathic drugs and maintenance of records. 9. Important Rules at a Glance Rule Subject Rule 2(dd) Definition of Homoeopathic medicines Rules 67A–67H Sale of Homoeopathic medicines Rule 67A Licensing Authority and application for sale license Rule 67C Forms 20-C and 20-D for sale Rules 85A–85I Manufacture of Homoeopathic medicines Rule 85C New Homoeopathic medicines Rule 85D Manufacturing license — Form 25-C Rule 85E Conditions for grant/renewal of manufacturing license

4.3 LICENSING REQUIREMENTS FOR MANUFACTURING AND SALES Rule Subject Schedule M-I Requirements for manufacturing premises/GMP Labelling provisions Potency, manufacturer, ingredients, batch and other particulars Schedule K Certain exemptions/conditions relating to specified drugs The manufacture, sale, stocking, exhibition for sale and distribution of Homoeopathic medicines in India are regulated under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. The Rules contain separate provisions for sale licences (Part VI-A) and manufacturing licences (Part VII-A). Licensing authority The State Government appoints the Licensing Authority for Homoeopathic medicines. Therefore, applications for manufacturing and sale licenses are generally made to the appropriate State/UT Drugs Control Department. For example, in Delhi, the Department of Drugs Control, Government of NCT of Delhi grants and renews licenses for the manufacture and sale of Homoeopathic medicines.

4.3.1 LICENSE FOR SALE OF HOMOEOPATHIC MEDICINES The principal provisions are Rules 67A–67G. a) Application for sale license An application for a license to sell, stock, exhibit or offer for sale, or distribute Homoeopathic medicines is made in: Purpose Application Form License Form Retail sale Form 19-B Form 20-C Wholesale sale/distribution Form 19-B Form 20-D These forms are specifically provided for Homoeopathic medicines under the Rules. A separate license is required for each place where medicines are sold or stocked for sale. Rule 67D addresses sale from more than one premises. b) Conditions for the sale premises Under Rule 67F, the Licensing Authority must be satisfied that: • the premises are clean; • in the case of a Form 20-C retail license, the sale premises are under the charge/supervision of an appropriately qualified competent person; • the prescribed qualifications of the competent person are fulfilled.

Following the 2017 amendment, the competent person for a Homoeopathic sale license may have, among other specified qualifications: 1. a degree in Homoeopathy from a recognised university; 2. a degree in Pharmacy from a recognised university; 3. a Bachelor's degree from a recognised university plus one year's experience dealing with Homoeopathic medicines in the specified settings; 4. a Diploma in Homoeopathic Pharmacy; or 5. a Diploma in Homoeopathy Medicine and Surgery. The Rules also contain a proviso concerning persons already registered as competent persons before the 2017 amendment. c) Conditions after grant of sale license The licensee must, among other things: • maintain the sale/storage premises in a clean condition; • conduct sale under appropriate competent-person supervision; • permit inspection by Drug Inspectors; • maintain prescribed records, particularly for Homoeopathic medicines containing alcohol; • comply with the conditions printed on Form 20-C or Form 20-D. The Rules provide specific record exemptions for certain small-volume potentised preparations and mother tinctures under the applicable conditions. d) Duration Under Rule 67E, a sale license is generally valid for five years, unless suspended or cancelled earlier, subject to the renewal

provisions. The renewal certificate for Forms 20-C and 20-D is issued in Form 20-E. 4.3.2 LICENSE FOR MANUFACTURE OF HOMOEOPATHIC MEDICINES The principal provisions are Rules 85A–85I. a) Manufacturing license A person intending to manufacture Homoeopathic medicines for sale or distribution must obtain a manufacturing license. The application is made in: Form 24-C → Manufacturing License in Form 25-C The official ONDLS service listing also identifies Form 24-C as the application for manufacture of Homoeopathic medicines and Form 25-C as the corresponding license. b) Separate manufacturing premises If Homoeopathic medicines are manufactured at more than one set of premises, a separate application and separate license are required for each set of premises under Rule 85A. c) Manufacturing technical staff Rule 85E requires manufacture to be conducted under the direction and supervision of competent technical staff, including at least one whole-time employee meeting the prescribed qualification and experience requirements. The Rule specifies routes involving: • a Science graduate with Chemistry and prescribed manufacturing experience; • a Pharmacy graduate with prescribed experience; or

• the specified Homoeopathy qualification with prescribed experience. The precise qualification provision should be checked against the currently applicable consolidated Rules and amendments at the time of licensing. d) Manufacturing premises and Schedule M-I The manufacturing premises must comply with the requirements of Schedule M-I. Rule 85E also provides requirements concerning manufacturing facilities and testing arrangements. For Delhi specifically, the Drugs Control Department states that manufacturing licences for Homoeopathic medicines can be granted only for premises located in approved Industrial Areas of Delhi. e) Laboratory and testing arrangements For manufacture of mother tinctures, Rule 85E requires adequate arrangements for: • identification of raw materials; • testing of mother tinctures, wherever possible; and • appropriate laboratory facilities or arrangements with an institution approved by the Licensing Authority for specified testing. f) Inspection before grant or renewal Under Rule 85EA, before granting or renewing a manufacturing licence, the Licensing Authority causes the manufacturing establishment to be inspected. The inspection may cover:

• premises; • plant and machinery; • manufacturing processes; • standardisation and testing arrangements; • qualifications of technical staff; • manufacturing equipment; • testing equipment; • Schedule M-I requirements; and • record-maintenance requirements under the Rules. Thus, merely submitting Form 24-C is not sufficient; the manufacturing facility must satisfy the regulatory inspection requirements. g) Special requirement for a "New Homoeopathic Medicine" A New Homoeopathic Medicine cannot simply be manufactured under an ordinary manufacturing license. Rule 85C provides that a New Homoeopathic Medicine requires prior approval by the appropriate Licensing Authority. The applicant must provide the required evidence and documentation concerning its therapeutic efficacy, including the prescribed proving requirements. Therefore: New Homoeopathic Medicine → Prior approval → Manufacturing license h) Important manufacturing conditions A Form 25-C licensee must: • maintain the prescribed technical staff and premises; • permit inspection and sampling by Drug Inspectors;

4.4 LABELING AND PACKAGING • maintain prescribed registers and records; • maintain an Inspection Book in Form 35; • follow special requirements relating to mother tinctures; • maintain records concerning identification of crude drugs; • maintain records of total solids and alcohol content of mother tinctures, as applicable; • observe hygienic manufacturing and storage conditions; and • comply with the applicable labelling and other requirements of the Rules. Records relating to specified mother-tincture tests are required to be maintained for five years under Rule 85H. i) Mother Tincture — additional regulatory requirements For a manufacturer of Homoeopathic mother tinctures, Rule 85H specifically requires attention to: Crude drug identification → Total solids → Alcohol content → Proper containers → Hygienic manufacture → Proper storage/handling The Rules require records of crude-drug identification, total solids and alcohol-content testing to be maintained for the prescribed period. The Drugs and Cosmetics Rules, 1945 prescribe requirements for the labelling, packing and presentation of drugs to ensure that medicines can be correctly identified, handled, stored and

used. The principal provisions are found in Rules 95–97, together with specific requirements for different categories of drugs and their relevant Schedules. Prohibition of sale unless properly labelled — Rule 95 No person shall sell or distribute a drug, including a patent or proprietary medicine, unless it is labelled in accordance with the Drugs and Cosmetics Rules, subject to applicable exceptions under the Rules. General requirements of labelling — Rule 96 The required particulars must generally be printed or written in indelible ink and appear conspicuously on: • The label of the innermost container of the drug. • Every other covering in which the container is packed. Important particulars include: 1. Name of the drug 2. Proper name of the drug, where applicable. 3. Trade name, where permitted. 4. Net contents expressed appropriately in weight, measure, volume, number of units or units of activity. 5. Quantities expressed using the metric system. 6. Other particulars prescribed according to the category of drug. Special requirements for Homoeopathic medicines For Homoeopathic medicines, the Rules prescribe additional labelling requirements. The label should indicate: • Name of the Homoeopathic medicine

• Potency • Name and address of the manufacturer • Name and address of the seller where the medicine is sold in a container other than the manufacturer's original container. • Importer details, where applicable. • Alcohol content, where applicable. Potency The potency of a Homoeopathic medicine is to be expressed in one of the recognised systems: • Decimal • Centesimal • Millesimal For example: Arnica montana 30C Nux vomica 6X Sulphur 1M The potency should be clearly associated with the medicine name. Homoeopathic medicines containing more than one ingredient Where a Homoeopathic medicine contains two or more ingredients, the label is required to state: • Name of each ingredient • Potency of each ingredient • Proportion of the ingredients, expressed in the metric system.

Alcohol declaration Where a Homoeopathic medicine contains alcohol, the label should state the percentage by volume of ethyl alcohol. There is a specific exemption for certain pharmacopoeial Homoeopathic medicines where the total quantity in the container is 30 ml or less, as provided in the Rules. Labelling of Homoeopathic Mother Tincture Homoeopathic mother tinctures have additional requirements. The label should include: a) Batch number A distinctive batch number must be provided, preceded by wording such as: Batch No. / Batch / Lot No. / Lot This enables the particular batch and its manufacturing records to be traced. b) Manufacturing License Number The manufacturing license number should be stated with an appropriate prefix, such as: Mfg. Lic. No. or Manufacturing Licence Number. c) Proprietary name A single-ingredient Homoeopathic medicine shall not bear a proprietary name on its label under the specific Homoeopathic labelling provision. Packaging requirements Packaging is important because it protects the drug from: • Contamination • Moisture • Light

• Physical damage • Deterioration • Adulteration • Accidental substitution The package should be appropriate to the nature, dosage form and stability requirements of the medicine. The immediate container and outer covering should permit the required information to remain legible and identifiable throughout the period for which the product is intended to be stored and used. Common levels of packaging Level Meaning Example Primary packaging Directly contacts the medicine Bottle, vial, tube Secondary packaging Outer package containing primary container Carton/box Tertiary packaging Used for transport/storage of multiple units Shipping carton Recent regulatory point The CDSCO's current Drugs Rules resources should be consulted for the latest amendments, because labelling requirements continue to be updated. For example, CDSCO lists a 2025 notification concerning inclusion of excipient details on every strip of medicines under Rule 96(7). Quick examination notes

4.5 RECORD AND REGISTERS Rule 95 → Prohibition of sale/distribution unless labelled Rule 96 → Manner of labelling Homoeopathic medicines → Specific requirements for name, potency, manufacturer, alcohol and multiple ingredients Mother tincture → Batch number and manufacturing licence number requirements Packaging → Protects the medicine and maintains its identity, quality and integrity. The Drugs and Cosmetics Rules, 1945 require licensed dealers to maintain appropriate records of the purchase, sale and supply of drugs. These records enable traceability of medicines, verification of transactions and inspection by the Drug Inspector. The current Rules are available through CDSCO (Central Drugs Standard Control Organization). 1. Cash/Credit Memo for Retail Sale Every retail supply of a drug is required to be supported by a cash or credit memo containing prescribed particulars, including: • Name and address of the dealer • Sale license number • Serial number of the cash/credit memo • Name of the drug • Quantity supplied The dealer should retain the carbon/duplicate copy as a record.

2. Retail Purchase Records Records of drugs purchased for retail sale should contain: 1. Date of purchase 2. Name and address of the supplier 3. Supplier's relevant drug license number 4. Name of the drug 5. Quantity purchased 6. Batch number 7. Name of the manufacturer Purchase bills/cash or credit memos should be serially numbered and maintained chronologically. 3. Records of Wholesale Sale Wholesale sales are made against a cash or credit memo containing: • Date of sale • Name and address of the purchaser/licensee • Purchaser's sale licence number, where applicable • Name of drug • Quantity • Batch number • Name of manufacturer • Signature of the competent person under whose supervision the sale was made Carbon copies of wholesale cash/credit memos are required to be preserved for three years from the date of sale.

4. Wholesale Purchase Records For drugs purchased for resale or sold by wholesale, records should include: Particular Details Date Date of purchase Supplier Name and address License Relevant license number Drug Name of drug Quantity Quantity purchased Batch Batch number Manufacturer Name of manufacturer Purchase bills and cash/credit memos should be maintained in serially numbered chronological order. 5. Prescription Register For certain prescription medicines, a prescription register may be maintained. The register can include: • Serial number • Date of supply • Name and address of prescriber • Name and address of patient • Name of drug/preparation • Quantity supplied • Manufacturer • Batch number • Date of expiry/potency, where applicable

• Signature of the Registered Pharmacist/person under whose supervision the medicine was supplied These requirements are particularly relevant to drugs covered by Schedule C, H and H1, as applicable. 6. Schedule H1 Register A separate register is specifically required for Schedule H1 drugs. At the time of supply, the following particulars must be recorded: • Name and address of the prescriber • Name of the patient • Name of the drug • Quantity supplied The Schedule H1 records must be maintained for three years and kept available for inspection. Table Record/Register Main purpose Important retention Cash/Credit Memo Retail/wholesale sale documentation As prescribed Retail Purchase Record Traceability of purchased stock General rule applies unless otherwise specified Wholesale Sale Memo Record of wholesale supply 3 years for carbon copies Wholesale Purchase Record Traceability of wholesale purchases General rule applies Prescription Register Prescription-based supply As prescribed Schedule H1 Monitoring H1 drug 3 years

4.6 INSPECTION, SAMPLING AND TESTING OF HOMOEOPATHIC DRUGS Register supply Schedule X Register Detailed transaction & stock control As prescribed Purchase Bills Evidence of procurement Chronological record The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 provide a regulatory framework for ensuring the quality, safety and compliance of Homoeopathic medicines. For Homoeopathic drugs, important provisions include Rules 2(dd), 30AA, 67(C–H), 85(A–I), 106-A, Schedule K and Schedule M-I, along with the applicable standards in the Second Schedule to the Act. 1. Inspection of Homoeopathic Drug Premises Inspection is the examination of a manufacturing, storage or sale premises by an authorized Drug Inspector to verify compliance with the Act, Rules and license conditions. Objectives of inspection The main objectives are to: 1. Verify compliance with the conditions of the drug licence. 2. Examine the premises, plant and equipment. 3. Verify the manufacturing process. 4. Check storage conditions of Homoeopathic medicines. 5. Examine manufacturing and testing records.

6. Verify the qualifications and availability of technical staff. 7. Check whether medicines conform to prescribed quality standards. 8. Detect misbranded, adulterated or spurious drugs. 9. Collect representative samples for laboratory examination. 10. Verify compliance with applicable Good Manufacturing Practices (GMP). The licensing authority may require inspection before granting or renewing a manufacturing licence. Under Rule 85-EA, the Inspector examines the premises, plant, appliances, manufacturing process, standardization/testing arrangements and professional qualifications of technical staff. 2. Powers and Duties of the Inspector For licensed Homoeopathic manufacturing premises, Rule 85- H requires the licensee to permit an Inspector to enter the premises with or without prior notice, inspect the premises and take samples of manufactured Homoeopathic medicines. The Inspector may also examine registers and records and obtain information necessary to determine compliance with the Act and Rules. During inspection, the Inspector may examine: • Manufacturing areas • Raw-material storage • Finished-product storage • Dispensing and manufacturing equipment • Mother tincture preparation facilities • Potentization/dilution areas • Labelling and packing arrangements • Quality-control facilities

• Laboratory equipment • Batch manufacturing records • Testing records • Purchase and stock records • Distribution/sale records • Inspection Book • License and statutory documents 3. Sampling of Homoeopathic Drugs Sampling means the collection of a representative quantity of a Homoeopathic drug by an authorized Inspector for examination or analysis. The principal purpose is to determine whether the drug complies with the prescribed identity, quality, purity and strength requirements. The regulatory authorities use sampling from manufacturing and sale premises as part of quality surveillance. For example, the Delhi Drugs Control Department states that samples are collected from manufacturing and sale premises for testing/analysis to check the quality of drugs manufactured and sold in Delhi. Sources from which samples may be collected Samples may be obtained from: • Manufacturing premises • Wholesale premises • Retail premises • Stockists /distributors • Other premises where Homoeopathic medicines are stored or sold Points to be recorded during sampling

The Inspector should properly document details such as: • Name of the drug • Batch/Lot number • Manufacturer • License details • Date of manufacture • Expiry date, where applicable • Quantity collected • Pack size • Place of collection • Date of collection • Storage conditions • Name/signature of the person from whom the sample is taken • Sample identification/seal details Purpose of Sampling Sampling is carried out to determine whether the drug: Conforms to prescribed standards → YES → Acceptable Does not conform → NO → Further regulatory action The sample may be examined for: • Identity • Purity • Strength • Quality • Compliance with pharmacopoeial standards • Correct formulation/ingredients • Physical characteristics • Contamination or adulteration, where applicable • Labelling and packaging requirements

The official pharmacopoeial standards serve as an important basis for determining the quality of Homoeopathic medicines. The Government has stated that PCIM&H lays down pharmacopoeial standards and formulary specifications for Homoeopathy, which serve as official compendia for ascertaining drug quality. 5. Testing of Homoeopathic Drugs After collection, the sample is submitted to an appropriate laboratory for testing/analysis. The laboratory examination is intended to establish whether the sample meets the applicable statutory and pharmacopoeial requirements. A. Important areas of testing Depending upon the dosage form and applicable monograph, examination may include: a) Identity Determination that the substance or preparation is actually the Homoeopathic drug claimed on the label. b) Purity Determination that the drug is free from unacceptable impurities, contamination or adulteration. c) Strength Verification of the required strength or potency where a standard is prescribed. d) Physical examination Depending upon the dosage form: • Appearance • Colour

• Odour • Clarity • Uniformity • Solubility/dispersibility • Weight/volume • Other prescribed physical characteristics e) Pharmacopoeial tests Where a drug is covered by an applicable Homoeopathic pharmacopoeial monograph, the prescribed tests and specifications are followed. B. Laboratory Testing Testing may be undertaken through laboratories authorized/recognized under the applicable regulatory framework. The Government has also identified PCIM&H as the Central/appropriate appellate laboratory framework for testing or analysis of ASU&H drugs, including Homoeopathy, under the regulatory system. The testing laboratory should use appropriate validated/official methods and applicable pharmacopoeial specifications. C. Test Report After examination, the laboratory issues a report indicating whether the sample: Complies with the prescribed standard or Does not comply with the prescribed standard A non-compliant result may lead to further regulatory investigation and action by the competent authority.

D. Inspection–Sampling–Testing Procedure A useful way for students to remember the complete process is: Inspection of premises ↓ Examination of license & records ↓ Selection of drug/sample ↓ Collection of representative samples ↓ Documentation & sealing ↓ Submission to laboratory ↓ Laboratory testing/analysis ↓ Comparison with prescribed standards ↓ Test report ↓ Compliant → Record/closure Non-compliant → Investigation → Regulatory action

4.7 OFFENCES AND PENALTIES The Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 regulate the import, manufacture, distribution and sale of drugs and cosmetics in India. The principal penal provisions are contained in Sections 27 to 30 of the Act, while the Rules prescribe detailed requirements whose violation may attract these penalties. CDSCO currently publishes the Drugs Rules, 1945 and related amendments on its official website. The major “offences and penalties” are provided by the Drugs and Cosmetics Act, 1940, rather than by the Drugs Rules, 1945 themselves. The Rules establish many of the requirements, and contravention of those requirements can attract penalties under the Act. A. Manufacture, Sale or Distribution of Adulterated or Spurious Drugs A person who manufactures for sale, sells, stocks, exhibits, offers for sale or distributes a drug in contravention of the Act/Rules may be punished according to the nature and seriousness of the violation. Major categories include: Offence Punishment Adulterated/spurious drug likely to cause death or grievous harm Imprisonment of not less than 10 years, which may extend to life

imprisonment, and fine Certain other adulterated/spurious drugs Imprisonment and fine, with minimum terms depending on the category Other drugs manufactured/sold in contravention of the Act or Rules Imprisonment and fine, as prescribed under Section 27 Section 27 specifically covers manufacture, sale, stocking, exhibiting, offering for sale and distribution of drugs in contravention of the law. B. Manufacture or Sale of Misbranded Drugs Manufacturing, selling or distributing a misbranded drug is an offence. Examples may include: • Incorrect or misleading labelling • False claims on the label • Failure to comply with prescribed labelling requirements • Improper declaration of ingredients • Misleading representation regarding the nature or quality of the drug The penalty depends on the applicable provision and circumstances of the offence. C. Manufacture or Sale of Adulterated Drugs A drug may be considered adulterated when it does not meet the statutory requirements relating to purity, quality or composition. Examples include: • Contamination

• Addition or substitution of inferior substances • Unsanitary conditions of manufacture • Use of harmful or inappropriate substances • Failure to comply with prescribed standards Serious cases involving drugs likely to cause death or grievous harm attract particularly severe punishment under Section 27. D. Manufacture or Sale of Spurious Drugs A spurious drug is one that is falsely represented as another drug or manufactured under circumstances that make its identity or source deceptive. Manufacture, sale, stocking or distribution of spurious drugs is a serious offence and can result in substantial imprisonment and fines. E. Failure to Disclose the Name of Manufacturer Section 28 Failure to disclose information relating to the manufacturer, or contravention of the relevant provisions concerning disclosure, constitutes an offence. The current statutory provision provides for: • Imprisonment up to one year, or • Fine, or • Both. The monetary penalty has been increased by amendments to the Act. F. Failure to Maintain Records or Furnish Information Section 28A

Failure, without reasonable cause or excuse, to comply with requirements relating to: • Maintaining documents • Preserving records • Furnishing information • Producing required information to authorities is punishable under Section 28A. The provision provides for: • Imprisonment up to one year, or • Fine, or • Both. G. Contravention of Orders under Section 26A Section 28B Where the Central Government regulates, restricts or prohibits the manufacture, sale or distribution of a drug or cosmetic under Section 26A, contravention of such notification/order is an offence. Punishment may include: • Imprisonment up to three years, and • Fine up to ₹5,000 under the cited statutory text. H. Advertising Using Government Analyst's Report Section 29 A person cannot use a report or extract from a report of testing/analysis made by: • Central Drugs Laboratory, or • Government Analyst for advertising a drug or cosmetic. Violation is punishable with:

• Fine up to ₹500 under the cited provision. I. Penalty for Subsequent Offences Section 30 A person who has already been convicted of certain offences and is subsequently convicted again may receive enhanced punishment. For example, the cited statutory text provides substantially increased imprisonment and fine for a subsequent conviction under specified provisions of Section 27. J. Offences by Companies Where an offence is committed by a company, persons responsible for the conduct of the company's business may, subject to the statutory conditions and defences, also be proceeded against. This is particularly important for: • Pharmaceutical manufacturers • Wholesale distributors • Retail pharmacies • Drug companies • Laboratories • Importers K. Offences Relating to Licences Under the Drugs Rules, 1945, manufacture, sale, stocking or distribution of drugs is subject to prescribed licensing requirements and conditions.

Examples of violations include: • Manufacturing without a valid licence • Selling without the required licence • Violation of licence conditions • Failure to maintain prescribed premises • Failure to maintain required records • Failure to comply with storage requirements • Failure to comply with inspection requirements Such violations can lead to regulatory action including suspension or cancellation of license, seizure of drugs and prosecution where applicable. The Drugs Rules contain the detailed regulatory framework for licensing and compliance.

C H A P T E R - 5

C H A P T E R - 5 PHARMACY ACT, 1948 LEARNING OBJECTIVE ➢ To understand the general study of the Pharmacy Act with special reference to education regulation ➢ To understand the working of State and Central councils, the constitutions of these councils, and functions ➢ To understand the Registration procedure under the Act 5.1 INTRODUCTION OF PHARMACY ACT The Pharmacy Act of 1948 is an important legislation in India that governs the pharmacy profession and regulates the practice of pharmacy in the country. Here are some key features and provisions of the Pharmacy Act, 1948: • Pharmacy Council of India (PCI): The act establishes the Pharmacy Council of India, which is the statutory body responsible for the regulation and development of the pharmacy profession in India. The PCI consists of members appointed by the central government, including elected representatives from the pharmacy profession.

• State Pharmacy Councils: The act provides for the establishment of State Pharmacy Councils in each state of India. These councils are responsible for registering pharmacists, granting and renewing licenses, and regulating pharmacy education and practice within their respective states. • Registration of Pharmacists: The act mandates the registration of pharmacists to practice pharmacy. Only individuals who are registered with the State Pharmacy Council can legally practice as pharmacists and dispense medicines. • Qualification for Registration: The act specifies the minimum educational qualifications required for the registration of pharmacists. It recognizes pharmacy courses approved by the Pharmacy Council of India as the standard qualification for registration. • Code of Ethics: The act lays down a code of ethics for pharmacists, which outlines the professional conduct, responsibilities, and obligations expected from registered pharmacists. It emphasizes the importance of maintaining professional integrity, patient confidentiality, and providing quality pharmaceutical services. • Inspections and Disciplinary Actions: The act empowers the Pharmacy Councils to conduct inspections of pharmacy premises, investigate complaints against pharmacists, and take disciplinary actions in case of professional misconduct or violations of the code of ethics. • Education and Training:

The act regulates the education and training of pharmacists by setting standards for pharmacy education institutions and courses. It provides guidelines for curriculum, infrastructure, faculty, and examination processes to ensure the quality and competency of pharmacy graduates. • Central and State Government Powers: The act grants powers to the central and state governments to make rules and regulations regarding various aspects of pharmacy practice, education, and licensing. These rules are formulated to ensure compliance with the act and to address specific requirements of the pharmacy profession. The Pharmacy Act of 1948 plays a crucial role in maintaining the standards, ethics, and professionalism of the pharmacy profession in India. It aims to protect public health by ensuring that pharmacy practice is carried out by qualified and registered pharmacists who adhere to ethical practices and provide safe and effective pharmaceutical services. Professional ethics forms the cornerstone of pharmaceutical jurisprudence, guiding the conduct and decision-making processes of professionals within the pharmaceutical industry. These ethical principles are crucial for maintaining public trust, ensuring the integrity of the profession, and safeguarding the health and well-being of patients. This section explores the significance of professional ethics in pharmaceutical jurisprudence, highlighting its impact on legal compliance, patient safety, and professional accountability.

DID YOU KNOW ? The Pharmacy Act, 1948, was enacted to regulate the education and practice of pharmacy in India. It aimed to standardize qualifications and improve professionalism within the pharmaceutical sector. 5.2 GENERAL STUDY OF THE PHARMACY ACT, 1948 With special reference to education regulations The Pharmacy Act, of 1948, is a landmark legislation in India that governs the profession of pharmacy and ensures the proper maintenance of standards in pharmaceutical education and practice. This chapter provides a comprehensive overview of the Pharmacy Act, 1948, with a special focus on the education regulations it establishes. The Act aims to regulate the profession and practice of pharmacy in India to ensure that the public receives safe and effective pharmaceutical care. 5.2.1 HISTORICAL BACKGROUND Before the enactment of the Pharmacy Act, of 1948, there was no standard regulation governing pharmacy practice in India. The need for a structured framework became evident to ensure that pharmacists were properly educated and competent. The

All-India Pharmacy Council and State Pharmacy Councils were established under this Act to regulate the profession. 5.2.2 OBJECTIVES OF THE PHARMACY ACT, 1948 The main objectives of the Pharmacy Act, 1948, are: • To regulate the profession of pharmacy in India. • To ensure the establishment of Pharmacy Councils at both the central and state levels. • To prescribe minimum standards of education required for qualification as a pharmacist. • To regulate the practice of pharmacy to ensure high standards of pharmaceutical services. 5.2.3 STRUCTURE OF THE PHARMACY ACT, 1948 The Act is divided into five chapters: 1. Chapter I: Preliminary 2. Chapter II: The Pharmacy Council of India 3. Chapter III: State Pharmacy Councils 4. Chapter IV: Registration of Pharmacists 5. Chapter V: Miscellaneous Each chapter addresses different aspects of the regulation and governance of the pharmacy profession.

5.2.3 THE PHARMACY COUNCIL OF INDIA (PCI) The Pharmacy Council of India (PCI) is the central body constituted under Chapter II of the Act. It is responsible for setting standards of education and ensuring their implementation. The PCI's functions include: 1. Prescribing Minimum Standards of Education: The PCI prescribes the minimum standards of education required for qualification as a pharmacist, including the curriculum and syllabi for pharmacy courses. 2. Approval of Institutions: The PCI grants approval to institutions that meet its prescribed standards and can offer pharmacy education. 3. Inspection and Monitoring: Regular inspections are conducted by the PCI to ensure compliance with its standards. 5.2.4 STATE PHARMACY COUNCILS Chapter III of the Act provides for the establishment of State Pharmacy Councils. These councils are responsible for the registration of pharmacists and ensuring that pharmacy practice in their respective states adheres to the prescribed standards. Their functions include: 1. Registration of Pharmacists: Maintaining a register of qualified pharmacists within the state. 2. Regulation of Practice: Ensuring that pharmacists comply with ethical and professional standards. 3. Conducting Inspections: Regularly inspecting pharmacy establishments to ensure compliance with regulations.

5.2.5 IMPORTANCE OF EDUCATION REGULATIONS The education regulations under the Pharmacy Act, 1948, are crucial for maintaining high standards in the pharmacy profession. They ensure that pharmacists are well-trained and competent to provide healthcare services. Key benefits include: 1. Standardization: Ensures uniformity in pharmacy education across the country. 2. Quality Assurance: Regular inspections and approvals maintain the quality of education. 3. Professional Competence: Adequate training prepares pharmacists to meet the healthcare needs of the public effectively. The Pharmacy Act, 1948, with its comprehensive provisions and education regulations, plays a pivotal role in regulating the pharmacy profession in India. By ensuring high standards of education and practice, the Act safeguards public health and upholds the integrity of the pharmaceutical profession. The establishment of the Pharmacy Council of India and State Pharmacy Councils under the Act provides a robust framework for overseeing the education and practice of pharmacy, making it a critical piece of legislation in the field of healthcare in India.

5.3 THE WORKING OF STATE AND CENTRAL COUNCILS, The constitutions of these councils, and functions 5.3.1 CENTRAL COUNCIL The Central Pharmacy Council of India is constituted under the Pharmacy Act, 1948. It is a statutory body under the Ministry of Health and Family Welfare. Members: • Six members, among whom at least one teacher of each of the subjects of pharmacy, pharmaceutical chemistry, and pharmacognosy, elected by the University Grants Commission. • Six members elected by the Medical Council of India from amongst themselves. • One member elected by each State Pharmacy Council, who must be a registered pharmacist. • One member to represent each state nominated by the respective State Government. • One member to represent each Union Territory nominated by the Central Government. • A representative of the Directorate General of Health Services. • The Drugs Controller of India or an officer nominated by him. • The Director of the Central Drugs Laboratory, Calcutta.

• One member elected by the Pharmaceutical Society of India. Functions of the central council 1. Education Regulation: Formulating and amending regulations related to the minimum standard of education required for qualification as a pharmacist. 2. Approval of Courses and Institutions: Approving the courses of study and examinations for pharmacists in India and recognizing the qualifications granted by institutions. 3. Maintenance of Central Register: Maintaining a central register of pharmacists. 4. Inspection: Inspecting institutions seeking approval under the Act. 5. Advisory Role: Advising the Central and State Governments on matters related to pharmacy education and practice. 5.3.2 STATE PHARMACY COUNCIL: Constituted in each state under the Act, the State Pharmacy Council works under the respective state government's purview. Members: Six members elected by registered pharmacists of the state from amongst themselves. Five members, of whom at least one shall be a registered pharmacist, nominated by the State Government. One member elected by the Medical Council of the state from amongst themselves.

The Chief Administrative Medical Officer of the state. The Government Analyst under the Drugs and Cosmetics Act, 1940. Functions of the state councils 1. Registration of Pharmacists: Registering pharmacists and issuing registration certificates. 2. Education and Training: Ensuring that the institutions imparting education and training to pharmacists comply with the prescribed standards. 3. State Register Maintenance: Maintaining a register of pharmacists practicing in the state. 4. Conduct of Examinations: Conducting examinations for the qualifying degree and diploma courses in pharmacy. 5. Inspection: Conducting periodic inspections of the institutions providing pharmacy education. 5.3.3 WORKING OF CENTRAL AND STATECOUNCILS 1. Meetings: Both councils meet at prescribed intervals to discuss and make decisions on pertinent issues. The Central Council generally meets at least twice a year, while the frequency of State Council meetings may vary. 2. Committees: Various committees are formed within these councils to handle specific tasks like education, ethics, registration, etc. 3. Executive Functions: Executing decisions and implementing regulations through a Secretariat, which assists in the day-to-day functioning. 4. Coordination: The Central Council works in close coordination with State Councils to ensure uniform

standards in pharmacy education and practice across the country. This structure and these functions ensure the standardization and regulation of pharmacy education and practice in India, contributing to the healthcare system's efficiency and effectiveness. DID YOU KNOW ? The Pharmacy Act, 1948, was amended in 1955 to include provisions for the registration of pharmacists and the constitution of the Pharmacy Council of India, which acts as the apex body for pharmacy education and practice in the country. 5.4 REGISTRATION PROCEDURE The Pharmacy Act, 1948, outlines the procedure for the registration of pharmacists in India. The registration process ensures that only qualified individuals are allowed to practice pharmacy. Here is a detailed description of the registration procedure under the Act:

5.4.1 State Register of Pharmacists Each State Pharmacy Council is responsible for maintaining a register of pharmacists. This register includes the names and qualifications of all pharmacists registered under the Act within that state. Eligibility criteria To be eligible for registration as a pharmacist, an individual must: • Have attained the age of 18 years. • Hold a qualification approved under Section 12 of the Pharmacy Act, 1948. This typically includes a degree or diploma in pharmacy from a recognized institution. • Have completed the prescribed period of practical training. Application for registration The registration process involves the following steps: 1. Application Submission: • The applicant must submit a duly filled application form to the State Pharmacy Council. • The form is usually available on the council’s official website or at their office. 2. Required Documents: • Proof of age (e.g., birth certificate, passport, or school leaving certificate). • Proof of educational qualifications (e.g., degree or diploma certificate). • Proof of practical training (e.g., certificate of internship or training).

• Proof of identity and address (e.g., Aadhaar card, passport, or voter ID). 3. Fee Payment: • The applicant must pay the prescribed registration fee. The fee amount and payment mode may vary by state. 5.4.2. VERIFICATION AND APPROVAL 1. Document Verification: • The State Pharmacy Council verifies the submitted documents to ensure the applicant meets the eligibility criteria. 2. Interview/Assessment (if applicable): • Some State Pharmacy Councils may conduct an interview or assessment to further evaluate the applicant’s knowledge and skills. 3. Approval and Entry into Register: • Upon successful verification and assessment, the applicant’s name is entered into the State Register of Pharmacists. • The council issues a registration certificate to the applicant, which serves as proof of their registration. 5.4.3 RENEWAL OF REGISTRATION 1. Validity: The registration is valid for a specified period, usually one to five years, depending on the state's regulations.

2. Renewal Process: • Registered pharmacists must apply for renewal before the expiry of their registration. • The renewal process involves submitting a renewal application form, paying the renewal fee, and providing proof of continuing education or practice. 3. Continuing Education: • Some states require pharmacists to complete a certain number of continuing education credits or professional development activities to be eligible for renewal. 5.4.4 REMOVAL AND RESTORATION OF NAMES 1. Removal from Register: • The State Pharmacy Council may remove a pharmacist’s name from the register if they are found guilty of misconduct, professional negligence, or if they fail to renew their registration. • Pharmacists may also request voluntary removal from the register if they wish to cease practicing. 2. Restoration to Register: • A removed pharmacist can apply for restoration by submitting a restoration application and paying the prescribed fee.

• The council may require proof of remedial education or training before restoring the pharmacist’s name to the register. 5.4.5 APPEALS If an application for registration, renewal, or restoration is denied, the applicant can appeal to the State Government or a designated appellate authority within a specified period. The registration procedure under the Pharmacy Act, 1948, ensures that pharmacists in India are adequately qualified and competent to practice, thus safeguarding public health and ensuring the standards of the profession.

Let’s revise! • Pharmacy Council of India (PCI): The act establishes the PCI, which regulates the profession and education of pharmacists in India. • Registration of Pharmacists: It mandates the registration of pharmacists and sets standards for their education and practice. • Qualifications for Registration: Specifies the qualifications required for individuals to be eligible for registration as pharmacists. • Constitution of State Pharmacy Councils: Each state has its own Pharmacy Council to oversee pharmacy practice within its jurisdiction. • Controlled Substances: Provides regulations regarding the manufacture and sale of drugs, including controlled substances, ensuring safety and efficacy.

• Penalties and Offenses: Outlines penalties for violations such as practicing without registration or selling drugs without a license. 1. What is the primary purpose of the Pharmacy Act, 1948? 2. Describe the composition and functions of the State Pharmacy Council as per the Pharmacy Act, 1948. 3. Outline the registration procedure for pharmacists under the Pharmacy Act, 1948. 4. What are the educational qualifications required for registration as a pharmacist under the Pharmacy Act, 1948? 5. Differentiate between the roles and responsibilities of the State Pharmacy Council and the Central Pharmacy Council under the Pharmacy Act, 1948.

C H A P T E R - 6

C H A P T E R - 6 THE DRUGS AND MAGIC REMEDIES (OBJECTIONABLE ADVERTISEMENTS) LEARNING OBJECTIVE ➢ To study Magic remedies and objectionable and permitted advertisements 6.1 INTRODUCTION OF DRUG AND MAGIC ACT The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 is an important legislation in India enacted to control and prohibit objectionable advertisements relating to drugs and remedies. The Act aims to protect the public from misleading claims, fraudulent representations, and advertisements that promote certain drugs or remedies for prohibited diseases and conditions. The Act regulates advertisements that may create false or exaggerated expectations regarding the diagnosis, prevention, treatment, or cure of diseases. It is particularly concerned with advertisements that exploit public health concerns or encourage the use of remedies through unscientific or misleading claims. The Act also places restrictions on advertisements relating to “magic remedies”, which include certain talismans, mantras, kavachas and other alleged remedies claimed to possess

miraculous powers for the diagnosis, prevention, treatment or cure of diseases or disorders. Objectives of the Act The major objectives are: 1. To prohibit objectionable advertisements concerning drugs and remedies. 2. To prevent misleading claims about the efficacy or therapeutic value of drugs. 3. To restrict advertisements for certain diseases and conditions specified under the Act. 4. To prohibit advertisements of magic remedies claiming miraculous therapeutic effects. 5. To protect the public from exploitation arising from false or exaggerated health claims. 6. To regulate promotional practices relating to drugs and remedies in the interest of public health. Scope and Importance in Pharmacy The Act is particularly relevant to pharmacy, pharmaceutical jurisprudence and healthcare practice because pharmacists, manufacturers, distributors and healthcare professionals may come across advertisements concerning medicines and therapeutic claims. Knowledge of this legislation helps ensure that drug-related promotional material is lawful, responsible and not misleading. The Act primarily deals with: • Prohibition of certain advertisements relating to drugs. • Restriction on advertisements claiming treatment or cure of specified diseases and conditions. • Prohibition of advertisements for certain magic remedies.

• Regulation of the manner in which therapeutic claims are made. • Penalties for contravention of the provisions of the Act. 6.1.1 MAGIC REMEDIES Definition and Scope: • Magic Remedy: According to the Act, a magic remedy includes any talisman, mantra, kavacha, or other charm that is claimed to possess miraculous powers for curing, diagnosing, preventing, or mitigating any disease in humans or animals, or for affecting or influencing the structure or function of the human or animal body. • The term extends to any article, substance, device, or process that purports to provide health benefits through magical or supernatural means. Common Types of Magic Remedies: • Talisman and Amulets: Objects believed to have magical powers to cure diseases or ward off illnesses. • Mantras and Incantations: Phrases or chants claimed to invoke supernatural powers for health benefits. • Kavachas: Protective charms or shields purported to offer health protections or cure ailments. Historical Context and Popular Beliefs: • Magic remedies have been part of traditional and folk medicine across cultures, often intertwined with cultural and religious beliefs.

• Despite their historical significance, these remedies often lack scientific validation and can lead to misinformation and exploitation of vulnerable populations. 6.1.2 IMPLICATIONS OF MAGIC REMEDIES: 1. Health Risks: • False Hope and Delay in Proper Treatment: Reliance on magic remedies can delay or prevent individuals from seeking proper medical treatment, leading to worsening of health conditions. • Potential Harm: Some magic remedies may involve the use of harmful substances or practices that can cause direct physical harm to individuals. 2. Economic Exploitation: • Vendors of magic remedies often exploit the desperation of patients, especially those suffering from chronic or incurable diseases, by charging exorbitant prices for ineffective products or services. 3. Misleading Claims: • Advertisements for magic remedies often make exaggerated or false claims about their efficacy, misleading the public and undermining • trust in scientifically proven medical treatments. 6.1.3 REGULATIONS AND PROHIBITIONS: 1.Prohibition of Advertisements:

• The Act strictly prohibits the advertisement of magic remedies. This includes any representation, by means of words, sounds, or visible representations, that suggests a remedy has magical properties or miraculous powers. 2.Legal Provisions: • Section 3: Prohibits the advertisement of certain drugs for the treatment of specific diseases and conditions listed in the Act. • Section 4: Prohibits the advertisement of magic remedies for the diagnosis, cure, mitigation, treatment, or prevention of any disease or condition in humans or animals. 3.Enforcement and Penalties: • Regulatory authorities are empowered to enforce the provisions of the Act, conduct inspections, and take necessary actions against violators. • Penalties for violating the Act include fines and imprisonment. The severity of penalties depends on the nature and extent of the violation. 4.Exemptions: • The Act provides certain exemptions, such as advertisements in scientific journals or materials intended for medical professionals, provided they comply with regulatory standards and do not mislead. 6.1.4 PUBLIC AWARENESS AND EDUCATION:

1.Role of Public Health Campaigns: • Raising awareness about the risks associated with magic remedies and the importance of seeking evidence-based medical treatments is crucial. • Public health campaigns can educate communities about the legal provisions of the Act and the dangers of relying on unverified remedies. 2.Encouraging Scientific Inquiry: • Promoting scientific research and validation of traditional remedies can help integrate effective traditional practices into mainstream medicine while discarding harmful or ineffective ones. The regulation of magic remedies under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, is essential for protecting public health and ensuring that individuals receive accurate information about medical treatments. By prohibiting the advertisement of unverified and potentially harmful remedies, the Act aims to prevent exploitation, safeguard health, and promote the use of scientifically validated medical treatments. Compliance with these regulations and continuous public education are key to achieving these goals. DID YOU KNOW ?

The Act empowers the Central Government to appoint a designated authority to scrutinize and regulate advertisements related to drugs and remedies.

6.2 OBJECTIONABLE AND PERMITTED ADVERTISEMENTS The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, was enacted to regulate the advertising of drugs and remedies and to prohibit advertisements that make false claims or promote the use of magical remedies. This section outlines the criteria for objectionable and permitted advertisements under the Act. 6.2.1 OBJECTIONABLE ADVERTISEMENTS: 1. Prohibited Claims: • Advertisements that claim to cure or prevent specific diseases and conditions listed in the Act are prohibited. This includes, but is not limited to: ➢ Venereal diseases (e.g., syphilis, gonorrhea) ➢ Sexual disorders (e.g., impotency, premature ejaculation) ➢ Serious ailments (e.g., cancer, diabetes, epilepsy, tuberculosis) ➢ Conditions related to menstruation and childbirth 2. False and Misleading Statements: • Advertisements that contain false or misleading claims about the efficacy of a drug or remedy. • Claims that suggest a drug or remedy has magical properties or supernatural powers.

3. Magic Remedies: • Any advertisement that promotes magic remedies, such as talismans, mantras, kavachas, or charms, that claim to cure or prevent diseases or affect bodily functions. 4. Unapproved Drugs: • Advertising drugs that have not been approved by the appropriate regulatory authorities for the claimed uses. 5. Unverified Claims: • Claims about the drug's ability to enhance physical or mental capabilities without scientific evidence. • Exaggerated benefits of the drug that cannot be substantiated by clinical studies. 6. Inappropriate Targeting: • Advertisements that target vulnerable populations, such as children, elderly individuals, or people suffering from chronic illnesses, with false promises of miraculous cures. 6.2.2 PERMITTED ADVERTISEMENTS: 1. Over-the-Counter (OTC) Drugs: • Advertisements for OTC drugs that are not included in the prohibited list and meet regulatory standards. • Must provide accurate information about the drug, including its uses, dosage, side effects, and contraindications.

2. Educational and Informational Content: • Advertisements aimed at educating the public about health, hygiene, and preventive care, without making specific therapeutic claims. • Content that promotes general well-being and encourages healthy lifestyles. 3. Approved Drugs: • Advertisements for drugs that have been approved by regulatory authorities for specific uses, provided they comply with the standards set by the authorities. • Must include necessary warnings, precautions, and instructions for use. 4. Professional Medical Publications: • Advertisements in scientific journals or publications intended for healthcare professionals, provided they do not mislead and adhere to professional standards. • Must present factual information backed by scientific evidence. 5. Labeling Requirements: • Advertisements that comply with the labeling requirements specified by the Act, ensuring that all mandatory information is clearly presented. • Labels must include the name of the drug, active ingredients, dosage instructions, warnings, and the manufacturer’s details.

6. Preventive and Public Health Campaigns: • Advertisements promoting vaccination, sanitation, and other public health measures approved by health authorities. • Campaigns that align with public health policies and provide accurate, helpful information. 6.2.3 ENFORCEMENT AND PENALTIES: 1. Regulatory Authorities: • The Act empowers regulatory authorities to monitor and enforce compliance with its provisions. • Authorities can inspect advertisements and take action against violators, including issuing fines and imprisonment. 2. Penalties: • Penalties for violating the Act include fines and imprisonment. The severity of the penalty depends on the nature and extent of the violation. • Repeat offenders may face harsher penalties to deter future violations. 3. Consumer Protection: • Mechanisms are in place for consumers to report misleading advertisements and seek redressal. • Consumer protection agencies play a role in enforcing the Act and protecting public health.

The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, is designed to protect the public from false and misleading advertisements related to drugs and magic remedies. By defining what constitutes objectionable and permitted advertisements, the Act aims to ensure that consumers receive accurate and reliable information about medical treatments. Compliance with these regulations helps maintain public trust in the healthcare system and promotes the use of scientifically validated treatments. Let’s revise! • Magic Remedies: ➢ Defined as any talisman, mantra, amulet, or any other object claimed to possess magical powers. ➢ Prohibition on advertisements claiming to cure certain diseases using such remedies. • Objectionable Advertisements: ➢ Define objectionable advertisements. Explain the objectives, scope, and important provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. ➢ Discuss the advertisements prohibited under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Give suitable examples of claims that may be considered objectionable. ➢ Explain the provisions relating to advertisements of drugs for the diagnosis, treatment, mitigation, or prevention of

diseases and disorders under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. ➢ What are the diseases and conditions for which advertisements relating to drugs are prohibited? Explain the relevant provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. ➢ Discuss the restrictions on advertisements claiming to promote or improve sexual capacity or performance. Explain the relevant provisions with examples. • Prohibits advertisements that: ➢ Offer a drug as a remedy for infertility without scientific validation. ➢ Claim to cure certain diseases specified in the Act. ➢ Mislead the public regarding the nature, substance, quality, or properties of the drug. • Permitted Advertisements: ➢ Advertisements that adhere to the guidelines set forth in the Act. ➢ Must not contravene any provisions of the Drug and Cosmetics Act, 1940. • Regulatory Framework: ➢ The Act empowers authorities to take action against misleading advertisements. ➢ Penalties for violations include fines and imprisonment.

• Public Awareness: ➢ Encourages public awareness regarding the dangers of misleading drug advertisements. ➢ Promotes responsible advertising practices in the pharmaceutical industry. 1. What constitutes a "magic remedy" under the Drugs and Magic Remedies (Objectionable Advertisements) Act? Provide examples. 2. What types of claims are prohibited in drug advertisements under the Act? Give examples of diseases that cannot be claimed to be cured by drugs in advertisements. 3. How does the Act empower regulatory authorities to address objectionable advertisements? Describe the penalties for violating the advertising guidelines. 4. What are the criteria for advertisements that are permitted under the Drugs and Magic Remedies (Objectionable Advertisements) Act? How do these advertisements differ from objectionable ones? 5. Why is public awareness important in the context of regulating drug advertisements? How does the Act aim to

promote responsible advertising practices in the pharmaceutical industry?

C H A P T E R - 7

C H A P T E R - 7 NARCOTIC DRUG AND PSYCHOTROPIC SUBSTANCES ACT, 1985 LEARNING OBJECTIVE ➢ A brief study of the act with special reference to its objectives, offenses, and punishments 7.1 INTRODUCTION OF NDPS ACT, 1985 The Narcotic Drugs and Psychotropic Substances Act (NDPS Act), 1985, is a comprehensive piece of legislation enacted by the Indian Parliament to regulate and control the operations related to narcotic drugs and psychotropic substances. The Act aims to curb the menace of drug abuse and illicit drug trafficking while ensuring the legitimate use of these substances for medical and scientific purposes. It addresses the growing concerns over the misuse of narcotic drugs and psychotropic substances, which pose significant threats to public health and safety, social stability, and national security. India, being a signatory to various international conventions such as the Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic Substances, 1971, has

obligations to control and regulate the use of narcotic drugs and psychotropic substances within its territory. The NDPS Act was formulated to fulfill these international commitments and provide a robust legal framework to tackle drug-related issues domestically. The Act covers a broad spectrum of activities, including the cultivation, production, manufacture, possession, sale, purchase, transport, warehousing, use, consumption, import, and export of narcotic drugs and psychotropic substances. It lays down stringent provisions for the regulation and control of these activities, thereby ensuring that such substances are used only for legitimate purposes. One of the key features of the NDPS Act is its focus on stringent penalties and punishments for offenses related to narcotic drugs and psychotropic substances. The Act prescribes severe punishments, including long-term imprisonment, hefty

fines, and in certain aggravated cases, the death penalty. This reflects the seriousness with which the Indian legal system views drug-related offenses and its commitment to deterring individuals and organizations from engaging in such illegal activities. The NDPS Act also empowers various authorities and enforcement agencies, such as the Narcotics Control Bureau (NCB), to effectively implement its provisions. These agencies are tasked with monitoring and regulating the activities related to narcotic drugs and psychotropic substances, conducting investigations, and ensuring compliance with the law. In summary, the NDPS Act, 1985, represents India's comprehensive approach to addressing the multifaceted challenges posed by narcotic drugs and psychotropic substances. It balances the need for stringent control and regulation with provisions for the legitimate medical and scientific use of these substances, aiming to protect public health, safety, and social order. 7.2 OBJECTIVES OF THE NDPS ACT, 1985 The Narcotic Drugs and Psychotropic Substances Act, 1985 (NDPS Act), was enacted with several key objectives aimed at controlling and regulating the operations related to narcotic drugs and psychotropic substances. These objectives are designed to curb the abuse of these substances, prevent their illicit trafficking, and ensure their legitimate use for medical and scientific purposes. The primary objectives of the NDPS Act, 1985, include:

1. Prevention and Control of Drug Abuse: To combat the growing problem of drug abuse, which poses significant threats to public health, social stability, and individual well-being. The Act aims to reduce the demand for narcotic drugs and psychotropic substances through strict regulation and control. 2. Regulation of Operations: To regulate the cultivation, production, manufacture, possession, sale, purchase, transport, warehousing, use, consumption, import, and export of narcotic drugs and psychotropic substances. The Act ensures that these activities are conducted only under authorized and controlled conditions to prevent misuse and diversion into illegal channels. 3. Legal Framework for Enforcement: To provide a comprehensive legal framework that empowers law enforcement agencies to take effective measures against drug trafficking and abuse. The Act includes provisions for the detection, investigation, prosecution, and punishment of offenses related to narcotic drugs and psychotropic substances. 4. International Obligations: To fulfill India’s commitments under various international treaties and conventions related to the control and regulation of narcotic drugs and psychotropic substances. These include the Single Convention on Narcotic Drugs, 1961, the Convention on Psychotropic Substances, 1971, and the United Nations

Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. 5. Deterrence of Drug Trafficking: To deter individuals and organizations from engaging in the illegal trade of narcotic drugs and psychotropic substances through stringent penalties and punishments. The Act prescribes severe consequences for those involved in the illicit production, distribution, and trafficking of these substances. 6. Promotion of Legitimate Use: To ensure that narcotic drugs and psychotropic substances are available for legitimate medical and scientific purposes. The Act facilitates the use of these substances in healthcare and research, while preventing their diversion for non-medical uses. 7. Protection of Public Health and Safety: To protect public health and safety by controlling the availability and use of narcotic drugs and psychotropic substances. The Act aims to prevent the harm associated with drug abuse, such as addiction, overdose, and the spread of infectious diseases. 8. Support for Drug Rehabilitation and Treatment: To promote the treatment and rehabilitation of individuals affected by drug addiction. The Act encourages measures to provide medical care, counseling, and social support to drug dependents, aiding their recovery and reintegration into society.

By addressing these objectives, the NDPS Act, 1985, seeks to create a balanced approach to managing the challenges posed by narcotic drugs and psychotropic substances. It emphasizes both the control and regulation of these substances and the importance of their legitimate use for the benefit of society. 7.3 OFFENSES UNDER THE NDPS ACT, 1985 The Narcotic Drugs and Psychotropic Substances Act (NDPS Act), 1985, categorizes a wide range of activities related to narcotic drugs and psychotropic substances as offenses. These offenses are designed to cover various aspects of illicit activities, ensuring comprehensive control and regulation. The Act prescribes stringent penalties for these offenses to deter individuals and organizations from engaging in illegal drug- related activities. Below are the primary offenses under the NDPS Act: 1. Cultivation and Production: Unauthorized Cultivation: The cultivation of coca plants, opium poppy, or cannabis plants without proper authorization is prohibited. Unauthorized cultivation is considered a serious offense under the Act (Section 8, 18, 20). 2. Manufacture and Distribution: Unauthorized Manufacture: The manufacture, production, possession, sale, purchase, and transport of narcotic drugs and psychotropic substances without proper authorization are

strictly prohibited. This includes the production of any preparations containing narcotic drugs or psychotropic substances (Section 8, 9, 20). 3. Possession and Consumption: Unauthorized Possession: Possession of narcotic drugs and psychotropic substances without authorization is an offense. The Act distinguishes between small quantities and commercial quantities, prescribing varying degrees of penalties for each (Section 8, 21). Unauthorized Consumption: Consumption of narcotic drugs and psychotropic substances without authorization is also an offense. The severity of the punishment depends on the type and quantity of the substance involved (Section 27). 4. Import and Export: Unauthorized Import and Export: The import into and export from India of narcotic drugs and psychotropic substances without proper authorization is prohibited. This includes both commercial and personal quantities (Section 8, 23). 5. Sale and Purchase: Unauthorized Sale and Purchase: The sale and purchase of narcotic drugs and psychotropic substances without proper authorization is prohibited. This includes selling, purchasing, or dealing in these substances in any manner not covered by a valid license or permit (Section 8, 21). 6. Storage and Transportation: Unauthorized Storage and Transportation: Storing and transporting narcotic drugs and psychotropic substances without proper authorization is an offense. This includes warehousing these substances without the requisite permits (Section 8, 21).

7. Financing Illicit Trafficking and Harboring Offenders: Financing: Financing any activities related to the illicit trafficking of narcotic drugs and psychotropic substances is a serious offense. This includes providing funds or resources for such activities (Section 27A). Harboring Offenders: Providing shelter, protection, or assistance to individuals engaged in drug trafficking is prohibited. Harboring offenders involved in these illegal activities is a punishable offense (Section 27A). 8. Abetment and Criminal Conspiracy: Abetment: Encouraging, assisting, or facilitating the commission of an offense related to narcotic drugs and psychotropic substances is considered abatement and is punishable under the Act (Section 29). Criminal Conspiracy: Engaging in a conspiracy to commit any offense under the NDPS Act is treated as seriously as the commission of the offense itself. Participants in such conspiracies are subject to the same penalties as those for the principal offense (Section 29). 9. Attempt and Preparation: Attempt: Any attempt to commit an offense related to narcotic drugs and psychotropic substances is punishable under the Act. This includes any actions taken in preparation for committing the offense (Section 28). Preparation: Preparing to commit an offense related to narcotic drugs and psychotropic substances, such as gathering materials or making arrangements, is also an offense under the Act (Section 30)

DID YOU KNOW ? India's adherence to the Act is in line with its commitments under various international conventions on drug control, including the Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic Substances, 1971. 7.4 PUNISHMENTS UNDER THE NDPS ACT, 1985 The NDPS Act prescribes stringent punishments for various offenses, reflecting the severity of the crime and the potential harm to society. These punishments vary based on the nature and quantity of the substance involved: 1. Cultivation of Cannabis, Opium, or Coca Plants: Unauthorized cultivation can result in rigorous imprisonment of up to 10 years and a fine of up to ₹1 lakh. Repeat offenses can attract even harsher penalties. 2. Manufacture, Possession, Sale, Purchase, Transport, and Warehousing: Small Quantity: Imprisonment of up to 1 year, fine up to ₹10,000, or both. More than Small Quantity but Less than Commercial Quantity: Rigorous imprisonment of up to 10 years and a fine up to ₹1 lakh.

Commercial Quantity: Rigorous imprisonment of 10 to 20 years and a fine of ₹1 to ₹ 2 lakhs. The law allows for the death penalty in certain aggravated cases involving repeat offenses of large-scale drug trafficking. 3.Consumption of Narcotic Drugs or Psychotropic Substances: Cocaine, Morphine, Heroin: Imprisonment of up to 1 year, fine up to ₹20,000, or both. Other Drugs: Imprisonment of up to 6 months, fine up to ₹10,000, or both. The law encourages rehabilitation and treatment for addicts, recognizing the importance of addressing drug dependency. 4. Import and Export of Narcotic Drugs and Psychotropic Substances: Unauthorized import or export of narcotic drugs and psychotropic substances can lead to rigorous imprisonment of 10 to 20 years and a fine of ₹1 to ₹2 lakhs. Repeat offenders face harsher penalties, including the possibility of a death sentence. 5. Financing Illicit Trafficking and Harboring Offenders: Rigorous imprisonment of 10 to 20 years and a fine of ₹1 to ₹ 2 lakhs. The law aims to dismantle the financial and logistical networks supporting drug trafficking. 6. Repeat Offenses: Repeat offenders can face imprisonment up to 30 years and fines up to ₹ 3 lakhs. The Act includes provisions for enhanced penalties to deter habitual offenders.

7. Abetment and Criminal Conspiracy: Punishment for abetment and conspiracy is the same as the punishment for the principal offense, ensuring that all parties involved in drug-related activities are held accountable. 7.5 ENFORCEMENT AND REGULATORY BODIES 1. Central and State Authorities: The NDPS Act empowers both central and state governments to appoint officers and authorities for the enforcement of the Act. This includes the Narcotics Control Bureau (NCB) at the central level and various state-level agencies. 2. Narcotics Control Bureau (NCB): The NCB is the premier agency responsible for enforcing the NDPS Act, coordinating efforts between central and state authorities, and liaising with international agencies. 3. Special Courts: The Act provides for the establishment of special courts to expedite the trial of offenses under the NDPS Act, ensuring swift justice and deterrence.

7.6 CHALLENGES AND CRITICISMS 1. Implementation and Enforcement: While the NDPS Act provides a comprehensive legal framework, effective implementation and enforcement remain challenging due to resource constraints and the complex nature of drug trafficking networks. 2. Human Rights Concerns: The stringent penalties, including the death penalty, have been criticized by human rights organizations. There are concerns about the potential for abuse and the need for a balanced approach that includes rehabilitation and treatment. 3. Balancing Regulation and Access: Ensuring that legitimate medical and scientific use of narcotic drugs and psychotropic substances is not hindered while combating abuse and trafficking is a delicate balance that requires continuous monitoring and adjustment of policies. The NDPS Act, 1985, is a critical piece of legislation in India’s fight against drug abuse and illicit trafficking. By setting out stringent regulations and harsh penalties, the Act aims to protect public health and safety. However, effective implementation, balancing enforcement with human rights, and ensuring access to legitimate uses of these substances remain ongoing challenges. Understanding the objectives, offenses, and punishments under the NDPS Act is essential for law enforcement, legal professionals, and stakeholders in the healthcare and pharmaceutical sectors.